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A B S T R A C T
Background
Patients with chronic kidney disease (CKD) are at increased risk of coronary artery disease (CAD) and adverse cardiac events. Screening
for CAD is therefore an important part of preoperative evaluation for kidney transplant candidates. There is significant interest in the
role of non-invasive cardiac investigations and their ability to identify patients at high risk of CAD.
Objectives
We investigated the accuracy of non-invasive cardiac screening tests compared with coronary angiography to detect CAD in patients
who are potential kidney transplant recipients.
Search methods
MEDLINE and EMBASE searches (inception to November 2010) were performed to identify studies that assessed the diagnostic
accuracy of non-invasive screening tests, using coronary angiography as the reference standard. We also conducted citation tracking via
Web of Science and handsearched reference lists of identified primary studies and review articles.
Selection criteria
We included in this review all diagnostic cross sectional, cohort and randomised studies of test accuracy that compared the results of
any cardiac test with coronary angiography (the reference standard) relating to patients considered as potential candidates for kidney
transplantation or kidney-pancreas transplantation at the time diagnostic tests were performed.
Data collection and analysis
We used a hierarchical modelling strategy to produce summary receiver operating characteristic (SROC) curves, and pooled estimates
of sensitivity and specificity. Sensitivity analyses to determine test accuracy were performed if only studies that had full verification or
applied a threshold of ≥ 70% stenosis on coronary angiography for the diagnosis of significant CAD were included.
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Main results
The following screening investigations included in the meta-analysis were: dobutamine stress echocardiography (DSE) (13 studies),
myocardial perfusion scintigraphy (MPS) (nine studies), echocardiography (three studies), exercise stress electrocardiography (two
studies), resting electrocardiography (three studies), and one study each of electron beam computed tomography (EBCT), exercise
ventriculography, carotid intimal media thickness (CIMT) and digital subtraction fluorography (DSF). Sufficient studies were present
to allow hierarchical summary receiver operating characteristic (HSROC) analysis for DSE and MPS. When including all available
studies, both DSE and MPS had moderate sensitivity and specificity in detecting coronary artery stenosis in patients who are kidney
transplant candidates [DSE (13 studies) - pooled sensitivity 0.79 (95% CI 0.67 to 0.88), pooled specificity 0.89 (95% CI 0.81 to 0.94);
MPS (nine studies) - pooled sensitivity 0.74 (95% CI 0.54 to 0.87), pooled specificity 0.70 (95% CI 0.51 to 0.84)]. When limiting to
studies which defined coronary artery stenosis using a reference threshold of ≥ 70% stenosis on coronary angiography, there was little
change in these pooled estimates of accuracy [DSE (9 studies) - pooled sensitivity 0.76 (95% CI 0.60 to 0.87), specificity 0.88 (95%
CI 0.78 to 0.94); MPS (7 studies) - pooled sensitivity 0.67 (95% CI 0.48 to 0.82), pooled specificity 0.77 (95% CI 0.61 to 0.88)].
There was evidence that DSE had improved accuracy over MPS (P = 0.02) when all studies were included in the analysis, but this
was not significant when we excluded studies which did not avoid partial verification or use a reference standard threshold of ≥70%
stenosis (P = 0.09).
Authors’ conclusions
DSE may perform better than MPS but additional studies directly comparing these cardiac screening tests are needed. Absence of
significant CAD may not necessarily correlate with cardiac-event free survival following transplantation. Further research should focus
on assessing the ability of functional tests to predict postoperative outcome.
P L A I N L A N G U A G E S U M M A R Y
[Summary title]
[Summary text]
B A C K G R O U N D
Kidney transplantation remains the best treatment for patients
with end-stage kidney disease (ESKD) in terms of prolonging sur-
vival and improving quality of life. However, research has shown
that transplantation causes significant cardiovascular stress around
the time of the operation, and the incidence of myocardial in-
farction has been estimated to be approximately 5% (Gunnarsson
1984; Lentine 2005). Cardiovascular disease accounts for almost
half (40% to 55%) of all deaths following kidney transplanta-
tion (Briggs 2001). Screening for coronary artery disease (CAD)
is therefore an important part of evaluation for kidney transplan-
tation and a key decision tool to identify which patients need
specialised heart imaging tests (coronary angiography) and when.
Clinical practice varies considerably in how patients are selected
for testing; some centres test only those patients with significant
risk factors, others test all kidney transplant candidates; and in
which screening test is used (Hofmann 2008). The studies we
reviewed used tests such as dobutamine stress echocardiography
(DSE), myocardial perfusion scintigraphy (MPS) and stress elec-
trocardiography (EST) versus radiographic tests such as calcium
scoring, among others (Hofmann 2008).
Clinical practice guidelines from the American Society of Trans-
plantation (Kasiske 2001), United Kingdom Renal Association
(Dudley 2008) and Canadian Society of Transplantation (Knoll
2005) advise cardiac stress testing in potential transplant recipi-
ents who have symptoms or significant risk factors, but do not rec-
ommend a particular screening test. The guidelines indicate that
the test should be determined by local availability and expertise.
Although various screening tests for CAD are available, it remains
unclear which tests perform best for patients with ESKD.
Target condition being diagnosed
The target condition was significant CAD in potential kidney
transplant recipients. We defined significant CAD as the presence
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of at least 50% stenosis in at least one epicardial coronary artery
detected on coronary angiography.
Index test(s)
Any non- or minimally invasive test used to assess risk of CAD.
These included:
• Stress echocardiography (using either exercise or
pharmacological stress, such as DSE)
• MPS using either exercise or pharmacological stress
• EST
• Electron beam computed tomography (EBCT)
• Resting electrocardiography (ECG)
• Conventional echocardiography
• Exercise ventriculography
• Digital subtraction fluorography (DSF)
• Carotid intimal medial thickness (CIMT)
• Cardiopulmonary exercise testing
• Computed tomography (CT) coronary angiography
• Magnetic resonance angiography
• Cardiac magnetic resonance imaging.
Rationale
Severe CAD is strongly associated with the risk of myocardial in-
farction (MI) (Alderman 1993; Manoharan 2009). Non-invasive
cardiac screening tests may enable identification of kidney trans-
plant candidates who are at high risk of significant CAD. Such
tests are therefore useful in triaging patients for coronary angiog-
raphy, a test that provides confirmation of diagnosis and opportu-
nity for timely intervention (endovascular or open surgical inter-
vention, and aggressive risk factor modification, or both). There
is significant controversy about which tests should be used in the
screening process (Hofmann 2008). Although coronary angiogra-
phy is the gold standard for detecting coronary artery stenosis, it is
invasive, costly, and carries risk of nephrotoxicity, arrhythmia, MI,
stroke and femoral artery injury. Although anatomical depiction
derived from coronary angiography is a valuable diagnostic asset,
the test does not provide perfusion or contractility information
when the heart is under physiological stress. Non-invasive inves-
tigations such as DSE and MPS have moderate sensitivity and
specificity in detecting significant CAD in the general population
(Fleischmann 1998; Schinkel 2003). The applicability of these re-
sults in patients with ESKD who are potential kidney transplant
recipients is however uncertain. Common comorbidities among
patients with chronic kidney disease (CKD) are hypertension, car-
diomyopathy, calcific vascular disease and atherosclerosis. Com-
pared with the general population, these comorbidities may influ-
ence diagnostic test performance in people with CKD.
O B J E C T I V E S
We investigated the diagnostic accuracy of non-invasive cardiac
screening tests versus coronary angiography in potential kidney
transplant recipients. We provided summary estimates of diagnos-
tic accuracy for individual index tests to better understand the
utility and limitations of these non-invasive tests.
Secondary objectives
We compared the diagnostic accuracy among different screening
tests through:
1. Direct comparison: By analysing the results of studies that
assessed diagnostic accuracy of two or more tests in the same
population head-to-head.
2. Indirect comparison: By comparing the pooled results of
studies that assessed accuracy of screening tests in separate
populations.
The ability of screening tests to detect severe coronary artery steno-
sis (≥ 70% stenosis detected on coronary angiography) was also
assessed and compared among different screening tests.
Investigation of sources of heterogeneity
We also investigated if diagnostic accuracy varied among studies
with different prevalence of symptomatic chest pain and analysed
the effect. For this analysis, we included only studies that used
a threshold of ≥ 70% stenosis on coronary angiography for the
diagnosis of CAD. To avoid partial verification, we considered
effects among study participants who underwent both the index
test and coronary angiography. This methodology meant that we
were able to avoid partial verification.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included all diagnostic cross sectional studies, cohort studies
and randomised studies of test accuracy that compared cardiac test
accuracy with results obtained from coronary angiography (the
reference standard).
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Participants
Study participants included all patients who were considered to be
potential candidates for kidney transplantation or kidney-pancreas
transplantation at the time the diagnostic tests were performed.
Inclusion criteria
We included studies reporting outcomes relating to patients con-
sidered to be potential candidates for kidney transplantation or
kidney-pancreas transplantation at the time diagnostic tests were
performed. To ensure that our review was accessible and succinct,
we chose to limit the population to patients with CKD who were
considered candidates for kidney transplantation, but included all
possible tests used to diagnose CAD.
Exclusion criteria
Studies were excluded if they did not explicitly state that all study
participants were candidates for kidney transplantation. We also
excluded studies that investigated cardiac test accuracy in patients
with ESKD who were not transplant candidates (i.e. they were
unselected dialysis patients, not undergoing pre-transplant assess-
ment). Patients with ESKD who are not transplantation candi-
dates differ from patients who are transplant candidates with re-
spect to several key prognostic variables, such as age and fitness for
surgery. These differences in the key prognostic variables may re-
sult in differences in disease prevalence and test performance. We
also excluded studies which investigated patients with features of
acute coronary syndrome as our aim was to investigate the perfor-
mance of cardiac tests in a preoperative screening context. Where
it appeared that only some of the study participants were trans-
plantation candidates, we contacted the study authors requesting
separate data for only transplantation candidates.
Index tests
Any non- or minimally invasive test used to assess risk of CAD.
These included:
• Stress echocardiography (using either exercise or
pharmacological stress, e.g. DSE)
• MPS using either exercise or pharmacological stress
• EST
• EBCT
• ECG
• Conventional echocardiography
• Exercise ventriculography
• DSF
• CIMT
• Cardiopulmonary exercise testing
• CT coronary angiography
• Magnetic resonance angiography
• Cardiac magnetic resonance imaging.
Information regarding the various index tests including the type of
result produced, if cut-off values were present, and how differences
in cut-off points were handled, is provided in Table 1.
Comparator tests
Any of the listed index tests where they were compared with each
other versus the reference standard of coronary angiography.
Target conditions
Coronary artery stenosis was defined as at least 50% narrowing in
at least one epicardial coronary artery on coronary angiography.
We defined severe coronary artery stenosis as ≥ 70% stenosis on
coronary angiography.
Reference standards
Coronary angiography.
Search methods for identification of studies
Electronic searches
We searched the following resources.
• MEDLINE (OvidSP) 1950 - 1 November 2010
• EMBASE (OvidSP) 1980 - November 2010, Week 44
A Trials Search Co-ordinator of the Cochrane Renal Group (RM)
formulated specific search strategies for the MEDLINE and EM-
BASE searches (Appendix 1).
Citation tracking was performed using Web of Science. No re-
strictions were imposed in terms of language of publication or
publication status. To maximise the sensitivity of our search, we
avoided the use of methodology filters when searching for diag-
nostic accuracy studies because even the most sensitive filters have
been found to miss relevant studies (de Vet 2008; Doust 2005).
Searching other resources
We handsearched the reference lists of all primary studies and
reviews identified by the initial search.
Data collection and analysis
Selection of studies
Two authors independently reviewed the search results, first by
title and abstract, and where necessary by review of full text of the
study report, to determine inclusion or exclusion. Resulting sets
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of citations for inclusion were also compared. A third author was
available to arbitrate final decisions to include or exclude.
Data extraction and management
A standardised data extraction form was used to abstract study
design features and results data from each publication. For each
study data were extracted independently by two authors. We ex-
tracted: year of publication, country of study, study design, clin-
ical setting, definition of CAD (stenosis percentage on coronary
angiogram), the Quality Assessment of Diagnostic Accuracy Stud-
ies (QUADAS) methodological items (Reitsma 2009), prevalence
of cardiovascular risk factors in the study population (percentages
of participants on haemodialysis; with ESKD, diabetes mellitus
(DM), hypertension; who were male; with history of smoking;
and symptomatic of heart disease). We also recorded the numbers
of true positives, true negatives, false positives and false negatives.
These data were then collated in a spreadsheet. A third author was
available to adjudicate on disagreements.
Assessment of methodological quality
Methodological quality of included primary studies was assessed
by two authors using a modified QUADAS tool (Smidt 2008;
Whiting 2003) that included 11 of the 14 mandatory items (rep-
resentative spectrum, acceptable reference standard, acceptable
delay between tests, partial verification avoided, differential ver-
ification avoided, incorporation avoided, reference standard re-
sults blinded, index test results blinded, relevant clinical infor-
mation, uninterpretable results explained, withdrawals explained)
(Smidt 2008; Whiting 2003). The operational definitions of the
QUADAS items are presented in Appendix 2.
Statistical analysis and data synthesis
Extracted data were used to create forest plots of sensitivity and
specificity, to depict study-specific estimates of sensitivity and
specificity in receiver operating characteristic (ROC) space for each
index test, and to investigate:
1. the diagnostic performance of each index test
2. heterogeneity in the diagnostic performance of each index
test according to patient characteristics, study design, and study
quality factors (identified in Table 2 where sufficient data were
available)
3. the relative diagnostic performance of alternate tests based
on all available studies that provided data for at least one test,
and when the analysis was restricted to studies that provided data
for both tests.
Hierarchical summary receiver operating curve (HSROC) models
were fitted using the PROC NLMIXED procedure in SAS9.2®.
We applied the HSROC model to derive inferences about diag-
nostic test accuracy and heterogeneity in test performance where
sufficient studies (n ≥ 5) for tests were available. The HSROC
model used study specific estimates of sensitivity and specificity
to estimate the position and shape of the summary curve (Rutter
2001). The curve was defined by three parameters: threshold (the
underlying test positivity rate: a proxy for the cut-point that defines
a positive test); accuracy (the diagnostic log odds ratio); and shape
(the dependence of accuracy on threshold). Each study provided
an estimate for threshold and accuracy which were assumed to be
random effects in the model. When there was no evidence of an
association between accuracy and threshold, the summary curve
was considered symmetric and its position defined by a constant
diagnostic odds ratio (DOR). The model estimates were used to
obtain summary estimates for sensitivity, specificity, positive and
negative likelihood ratios, DORs and 95% confidence intervals
(CI), and the corresponding 95% confidence region for each index
test. The corresponding area under the curve (AUC) was com-
puted from the constant DOR as part of the analysis.
HSROC model results were used to create plots of estimated sum-
mary curves, summary points and confidence regions, superim-
posed on study-specific estimates of sensitivity and specificity.
We provided summary measures of diagnostic accuracy for:
1. all studies regardless of CAD threshold on coronary
angiography
2. studies that reported ≥ 70% stenosis threshold for
diagnosis of significant CAD on coronary angiography.
Pairwise comparisons of test performance among alternative index
tests were performed using data from studies where comparisons
between tests were made in the same study population (direct com-
parison) or in different study populations (indirect comparison).
A covariate of test type was included in the modelling to assess if
the SROC curves for tests differed in shape, or overall accuracy.
When comparing the relative performance of two index tests, we
initially assumed equal variances for random effects for the tests,
but extended the models to accommodate unequal variances for
random effects where required.
In studies reporting multiple tests in the same participants, results
were expressed separately for each test component.
Investigations of heterogeneity
Factors that could influence diagnostic accuracy other than true
test performance included those relating to methodological quality
and study design, characteristics of the underlying population, and
characteristics of the index and reference test. We detailed and
compared patient inclusion criteria for each included study. We
also investigated heterogeneity statistically by:
1. applying separate models to different subgroups
2. adding covariates to the hierarchical model.
Factors such as differences in study population characteristics (e.g.
prevalence of chest pain, hypertension and diabetes) and test ap-
plication (diagnostic test threshold, criteria for positive test, choice
of stress agent and stress protocol, and operator variability) were
used to explore any heterogeneity discovered in the analysis for
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each test separately, and to assess the impact of heterogeneity on
the relative accuracy across tests.
For index tests such as ECG and echocardiography, where different
definitions of an abnormal test were present, only data that had
been measured using the same definitions were combined.
Sensitivity analyses
Where differences were present across studies, we controlled for
heterogeneity by conducting sensitivity analyses. In particular, we
investigated diagnostic accuracy in studies that:
1. aimed to provide both index tests and reference tests to
their study population (studies that avoided verification bias)
2. applied a threshold of diagnosis of severe CAD of ≥ 70%
stenosis on coronary angiography
3. consisted entirely of asymptomatic individuals (studies that
excluded patients who had either symptoms of cardiac disease or
a history of ischaemic heart disease).
R E S U L T S
Results of the search
The results of electronic database and handsearching are outlined
in Figure 1. There were no disagreements between authors about
either the number of studies eligible for inclusion, nor data re-
sults (κ = 1.0). We identified 26 reports of 25 studies (35 compar-
isons in total). Seven studies compared more than one test versus
coronary angiography, and were interrogated to contribute data
to more than one test comparison (De Lima 2003; Gang 2007;
Garcia-Canton 1998; Garg 2000; Sharma 2005; Sharma 2009;
Vandenberg 1996). One study was reported twice (Sharma 2005),
and one study (Sharples 2004) could not contribute to the meta-
analysis because it reported results per coronary vessel, but not per
patient. The diagnostic and treatment pathway is presented at the
patient level, but including vessel-level analysis lead to inappro-
priate weighting in the combined analysis, and the potential for
bias from clustering of patients’ results. The details of all studies
included in the meta-analysis are reported in Characteristics of
included studies and Table 2.
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Figure 1. Flow of studies identified in literature search for systematic review of testing for coronary artery
disease in potential kidney transplant recipients* Some studies investigate more than one test and so
contribute to more than one test comparisonCIMT: carotid intimal medial thickness; DSE: dobutamine stress
echocardiography; DSF: digital subtraction fluorography; EBCT: electron beam computed tomography; ECG:
resting electrocardiography; Echo/LV: echocardiography (left ventricular dysfunction or cardiomegaly);
Echo/MAC: echocardiography (mitral annular calcification); Echo/RWMA: echocardiography (resting wall
motion abnormality); EST: exercise stress electrocardiography; EV: exercise ventriculography; MPS:
myocardial perfusion scintigraphy
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We identified a further 11 studies (Caglar 2006; Dahan 1995;
Dahan 1998; Dahan 2002; De Vriese 2009; Fujimoto 2006; Fukui
2005; Nishimura 2004; Ohtake 2005; Robinson 2007; Schmidt
2001) that reported diagnostic test accuracy in patients with CKD.
However, populations in these studies did not consist entirely of
patients who were being considered for kidney transplantation -
patients on dialysis or with CKD who were not being considered
for transplantation were also represented. These studies were ex-
cluded from the review because we were unable to obtain separate
data for potential kidney transplant recipients only from the au-
thors of these 11 studies. We excluded a total of 55 studies from
our review (see Characteristics of excluded studies).
Methodological quality of included studies
Results of the validity assessment are depicted (Figure 2; Figure 3)
for the 25 included studies, including Sharples 2004, which could
not contribute data. Only 10 included studies provided sufficient
information to enable scoring for the 11 nominated QUADAS
methodological items. Seven studies satisfied the QUADAS crite-
ria. All included studies satisfied the QUADAS criteria of includ-
ing study populations that represented the intended target popu-
lation (potential kidney transplant recipients) and an acceptable
reference standard (coronary angiography). Incorporation bias;
which occurs when the index test is incorporated in a compos-
ite reference standard, often leading to overestimation of diagnos-
tic test accuracy, was not present in any study. No patients were
verified with a second or third reference standard because disease
status (CAD) was diagnosed only by coronary angiography. Dif-
ferential verification was therefore also avoided in all studies. The
reference standard was not blinded to investigators in three studies
that reported coronary angiography being undertaken although
results of non-invasive index test were known to the investigators
(Brennan 1997; De Lima 2003; Gang 2007). It was unclear if
index test results were known at the time of coronary angiography
in seven studies (Bennett 1978; Cai 2010; Gowdak 2010; Jassal
2007; Krawczynska 1988; Reis 1995; West 2000). In one study
(De Lima 2003, author communication), coronary angiography
results were known to investigators who interpreted the index test.
It was also unclear if coronary angiography results were known
at the time of the index test in eight studies (Bennett 1978; Cai
2010; Gang 2007; Gowdak 2010; Jassal 2007; Krawczynska 1988;
Rosario 2010; West 2000). Of the 25 included studies, 20 aimed
to provide coronary angiography to all patients who underwent
index testing. However, only some participants who underwent
index testing proceeded to the reference test in five studies (Bates
1996; Brennan 1997; Cai 2010; Krawczynska 1988; Reis 1995).
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Figure 2. Methodological design and reporting quality of studies included in meta-analysis according to risk
of bias in quality domains assessed using the Quality Assessment of Diagnostic Accuracy Studies tool: review
authors’ judgements about each methodological quality item presented as percentages across all included
studies
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Figure 3. Methodological quality summary of studies: review authors’ judgements about each
methodological quality item for each included study using the Quality Assessment of Diagnostic Accuracy
Studies tool
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Findings
We identified 13 studies (745 participants) that evaluated DSE;
nine studies (582 participants) of MPS; two exercise EST stud-
ies (129 participants), and one study investigated each of EBCT
(97 participants), DSF (86 participants), exercise ventriculogra-
phy (35 participants) and CIMT (105 participants). Two stud-
ies (265 participants) investigated the relationship between rest-
ing wall motion abnormality on resting transthoracic echocardio-
graphy and significant CAD. One study (125 participants) also
investigated the relationship between mitral annulus calcification
on echocardiography and CAD. Another study (52 participants)
investigated the relationship between abnormal echocardiography
(left ventricular dysfunction or cardiomegaly) and CAD. Three
studies (263 participants) investigated the relationship between
abnormal resting ECG and CAD. No studies of diagnostic test
accuracy were identified for CT coronary angiography, cardiopul-
monary exercise testing, magnetic resonance angiography, or car-
diac magnetic resonance imaging.
A forest plot of the study estimates of sensitivity and specificity
for each test is shown in Figure 4. Figure 5 depicts the SROC plot
of sensitivity and specificity, arranged by test comparison, for all
studies (with one exception) identified and included in the meta-
analysis. Jassal 2007 was not included because sensitivity could
not be calculated due to a lack of patients with CAD.
11Cardiac testing for coronary artery disease in potential kidney transplant recipients (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 4. Accuracy of tests for coronary artery disease versus coronary angiography (forest plot); CIMT:
carotid intimal medial thickness; DSE: dobutamine stress echocardiography; DSF: digital subtraction
fluorography; EBCT: electron beam computed tomography; ECG: resting electrocardiography; Echo (LV):
echocardiography (left ventricular dysfunction or cardiomegaly; Echo (MAC): echocardiography (mitral
annular calcification); Echo (RWMA): echocardiography (resting wall motion abnormality); EST: exercise
stress electrocardiography; EV: exercise ventriculography; FN: false negative; FP: false positive; MPS:
myocardial perfusion scintigraphy; NS: not stated; TN: total negative; TP: total positive
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Figure 5. Summary receiver operator curve plot of sensitivity versus specificity for performance of different
tests versus coronary angiography. Each symbol represents a study, with the height and width of each symbol
being proportional to the inverse standard error of the sensitivity and specificity respectivelyCIMT: carotid
intimal medial thickness; DSE: dobutamine stress echocardiography; DSF: digital subtraction fluorography;
EBCT: electron beam computed tomography; ECG: resting electrocardiography; Echo (LV): echocardiography
(left ventricular dysfunction or cardiomegaly); Echo (MAC): echocardiography (mitral annular calcification);
Echo (RWMA): echocardiography (resting wall motion abnormality); EST: exercise stress electrocardiography;
EV: exercise ventriculography; MPS: myocardial perfusion scintigraphy
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Dobutamine stress echocardiography (DSE)
DSE was compared with coronary angiography in 13 studies (745
participants) (Bates 1996; Brennan 1997; Cai 2010; De Lima
2003; Ferreira 2007; Gang 2007; Garcia-Canton 1998; Herzog
1999; Jassal 2007; Reis 1995; Sharma 2005; Sharma 2009; West
2000). Using induced wall motion abnormalities during dobu-
tamine stress as a positive result indicating CAD, the sensitivity
of DSE varied from 44% to 96% and the specificity from 60%
to 100%. Overall, DSE had a DOR of 29.98 (95% CI 12.17 to
73.89) and area under the curve (AUC) of 0.91 (95% CI 0.85
to 0.95). The pooled sensitivity was 0.79 (95% CI 0.67 to 0.88),
specificity 0.89 (95% CI 0.81 to 0.94). One study also investigated
the relationship between peak systolic velocity during DSE for
CAD (Sharma 2009). This study reported that ≥ 50% elevation
in peak systolic velocity with exercise during DSE was associated
with ≥ 70% stenosis on coronary angiography (sensitivity 86%,
specificity 88%).
Not all patients who underwent index testing proceeded to have
these test results verified by the reference standard. Partial veri-
fication was made in three studies (Bates 1996; Brennan 1997;
Cai 2010). Furthermore, four studies (Bates 1996; Brennan 1997;
Jassal 2007; Reis 1995) used a reference test diagnostic threshold
of ≥ 50% stenosis. In the nine studies that used the higher thresh-
old of ≥ 70% stenosis, the pooled sensitivity was 0.76 (95% CI
0.60 to 0.87) and specificity 0.88 (95% CI 0.78 to 0.94) with
pooled DOR 23.01 (95% CI 8.08 to 65.51) and AUC 0.90. When
only studies that applied a reference standard threshold of ≥ 70%
stenosis and avoided partial verification were included, the pooled
sensitivity was 0.78 (95% CI 0.59 to 0.89), specificity 0.88 (95%
CI 0.76 to 0.94), positive likelihood ratio 6.44 (95% CI 3.03 to
13.70) and negative likelihood ratio 0.26 (95% CI 0.13 to 0.50)
with pooled DOR 25.22 (95% CI 7.68 to 82.80) and AUC 0.90.
Overall, there was very strong evidence of heterogeneity among the
13 studies (Figure 6). This remained highly statistically significant
even after accounting for differences in reference standard thresh-
old (Figure 7) and partial verification (Figure 8). The remaining
studies were similar in the performance of index test and interpre-
tation of test results, but two studies (Sharma 2005; Sharma 2009)
were responsible for most of the heterogeneity. There was no sta-
tistical evidence of heterogeneity in six studies (De Lima 2003;
Ferreira 2007; Gang 2007; Garcia-Canton 1998; Herzog 1999;
West 2000). Sharma 2005 and Sharma 2009 differed from other
studies in that they originated from a single research group and
had the highest proportion of patients who were symptomatic for
chest pain. Despite the hypothesis that prevalence of CAD may
have accounted for heterogeneity, we could not investigate any
relationship between diagnostic accuracy and prevalence of CAD
more formally because of the small number of studies, lack of
subgrouped patient data, and five studies (Bates 1996; Cai 2010;
Garcia-Canton 1998; Jassal 2007; West 2000) did not report pro-
portions of symptomatic patients. Two studies (Bates 1996; Gang
2007) enrolled only patients with DM, and sensitivity was found
to range from 47% to 90% and specificity from 86% to 95%.
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Figure 6. Summary receiver operator curve plot of sensitivity versus specificity for performance of different
tests versus coronary angiography: Indirect comparison MPS versus DSE. Each symbol represents a study, with
the height and width of each symbol being proportional to the inverse standard error of the sensitivity and
specificity respectively. The curves represent the summary receiver operator characteristic curves for MPS
and DSE. The circles represent the summary estimate of test performance and the zone outline surrounding it
represents the 95% confidence region of this summary estimateDSE: dobutamine stress echocardiography;
MPS: myocardial perfusion scintigraphy
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Figure 7. Summary receiver operator curve plot of sensitivity versus specificity for performance of different
tests versus coronary angiography: indirect comparison MPS versus DSE, according to reference standard
threshold. Each symbol represents a study, with the height and width of each symbol being proportional to the
inverse standard error of the sensitivity and specificity respectively. The curves represent the summary
receiver operator characteristic curves for MPS and DSE. The circles represent the summary estimate of test
performance and the zone outline surrounding it represents the 95% confidence region of this summary
estimateDSE: dobutamine stress echocardiography; MPS: myocardial perfusion scintigraphy
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Figure 8. Summary receiver operator curve plot of sensitivity versus specificity for performance of different
tests versus coronary angiography: indirect comparison MPS versus DSE, according to presence of partial
verification. Each symbol represents a study, with the height and width of each symbol being proportional to
the inverse standard error of the sensitivity and specificity respectively. The curves represent the summary
receiver operator characteristic curves for MPS and DSE. The circles represent the summary estimate of test
performance and the zone outline surrounding it represents the 95% confidence region of this summary
estimateDSE: dobutamine stress echocardiography; MPS: myocardial perfusion scintigraphy.
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Myocardial perfusion scintigraphy (MPS)
MPS was compared with coronary angiography in nine stud-
ies (582 participants) (Boudreau 1990; De Lima 2003; Garcia-
Canton 1998; Garg 2000; Gowdak 2010; Krawczynska 1988;
Marwick 1990; Vandenberg 1996; Worthley 2003). Sensitivity of
MPS varied from 29% to 100% and specificity from 31% to 88%.
The pooled summary estimates showed that MPS had a DOR
6.69 (95% CI 2.35 to 19.03) and AUC 0.78 (95% CI 0.64 to
0.88). The pooled sensitivity was 0.74 (95% CI 0.54 to 0.87),
and specificity 0.70 (95% CI 0.51 to 0.84).
All but one study (Krawczynska 1988) avoided partial verification
bias. Two studies (Garg 2000; Krawczynska 1988) used a threshold
of ≥ 50% stenosis and not the reference threshold of ≥ 70%
stenosis. When these studies were removed from the analysis, DOR
remained unchanged at 6.70 (95% CI 1.84 to 24.41) and AUC
0.78. The pooled sensitivity was 0.67 (95% CI 0.48 to 0.82),
specificity 0.77 (95% CI 0.61 to 0.88), with positive and negative
likelihood ratios of 2.89 (95% CI 1.39 to 5.99) and 0.43 (95%
CI 0.23 to 0.80) respectively.
There was very strong evidence of heterogeneity among the nine
studies (Figure 6). Heterogeneity remained even after account-
ing for differences in reference standard threshold (Figure 7) and
partial verification (Figure 8). Of the studies that had reference
standards of ≥ 70% stenosis and avoided verification bias, four
(Boudreau 1990; Garg 2000; Gowdak 2010; Vandenberg 1996)
enrolled only patients with DM. Heterogeneity among these four
studies of patients with diabetes remained strongly significant, al-
though heterogeneity of the other four studies (De Lima 2003;
Garcia-Canton 1998; Marwick 1990; Worthley 2003) decreased
when they were excluded. One study (Worthley 2003) that em-
ployed tachycardia pacing in some patients to ensure diagnostic
MPS had a much higher sensitivity and specificity compared with
the other studies and accounted for much of the remaining het-
erogeneity.
Meaningful investigation into whether prevalence of angina and/
or ischaemic heart disease symptoms on diagnostic test perfor-
mance was not possible as four studies (Garcia-Canton 1998; Garg
2000; Gowdak 2010; Krawczynska 1988) did not provide any in-
formation regarding prevalence of angina or ischaemic heart dis-
ease symptoms in their study populations.
Other tests
• Two studies (129 participants) (Bennett 1978; Sharma
2005) compared EST with coronary angiography. In Bennett
1978, only 4/7 participants were able to achieve an adequate
heart rate and had a diagnostic exercise stress test; the three
remaining participants underwent non-diagnostic tests due to
suboptimal stress capacity. Sensitivity for this study was 1.0 (95%
CI 0.29 to 1.0) and specificity 0 (95% CI 0 to 0.97). In Sharma
2005, which enrolled 125 participants, sensitivity was 0.36 (95%
CI 0.21 to 0.54) and specificity 0.91 (95% CI 0.83 to 0.96).
• One study (97 participants) (Rosario 2010) compared
EBCT with coronary angiography. This study reported that
when a calcium score threshold of 1330.72 Agatston units was
used as a cut-off point, sensitivity was 0.64 (95% CI 0.43 to
0.82) and specificity 0.65 (95% CI 0.53 to 0.76), using a
reference standard threshold of ≥ 70% stenosis to diagnose
CAD.
• One study (35 participants) (Vandenberg 1996) compared
exercise radionuclide ventriculography with coronary
angiography showing a sensitivity of 0.50 (95% CI 0.23 to 0.77)
and a specificity of 0.67 (95% CI 0.43 to 0.85)
• One study (86 participants) (Marwick 1989) compared
DSF with coronary angiography, showing a sensitivity of 0.78
(95% CI 0.61 to 0.90) and a specificity of 0.68 (95% CI 0.51 to
0.79).
• One study (105 participants) (Modi 2006) compared
CIMT with coronary angiography, showing a sensitivity of 0.90
(95% CI 0.77 to 0.97) and a specificity of 0.78 (95% CI 0.66 to
0.87).
• Three studies (Garg 2000; Sharma 2005; Sharma 2009)
correlated echocardiography findings with CAD. Two studies
(Sharma 2005; Sharma 2009) used resting wall motion
abnormality to define an abnormal index test. These studies,
which were performed by the same authors on similar
populations, had very similar sensitivity and specificity (Sharma
2005 reported sensitivity of 0.31 (95% CI 0.16 to 0.48) and
specificity of 0.96 (95% CI 0.89 to 0.99); Sharma 2009 found
sensitivity of 0.33 (95% CI 0.19 to 0.49) and specificity of 0.95
(95% CI 0.89 to 0.98)). Sharma 2005 also compared mitral
annular calcification and CAD and reported that this
echocardiographic finding had a sensitivity of 0.61 (95% CI
0.43 to 0.77) and specificity of 0.72 (95% CI 0.61 to 0.81).
Garg 2000 used echocardiographic criteria of left ventricular
dysfunction or cardiomegaly to define test positivity, and
reported sensitivity of 0.30 (95% CI 0.14 to 0.50) and specificity
of 0.80 (95% CI 0.59 to 0.93).
• Three studies (Gang 2007; Garg 2000; Sharma 2005)
investigated resting ECG for CAD diagnosis. In these studies,
abnormal resting ECG was defined as the presence of
pathological Q waves, left ventricular hypertrophy, ST depression
≥ 1 mm, ST elevation ≥ 1 mm, T wave inversion or bundle
branch block. However, results differed. Gang 2007 reported
sensitivity of 0.47 (95% CI 0.24 to 0.71) and specificity of 0.43
(95% CI 0.22 to 0.66); Garg 2000 identified sensitivity of 0.70
(95% CI 0.58 to 0.80) and specificity of 0.96 (95% CI 0.80 to
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1.00), and Sharma 2005 reported sensitivity of 0.75 (95% CI
0.58 to 0.88) and specificity of 0.84 (95% CI 0.75 to 0.91).
Comparative analysis: DSE versus MPS
Garcia-Canton 1998 and De Lima 2003 directly compared DSE
and MPS (Figure 9). Both studies reported that DSE had a higher
specificity and equivalent or better sensitivity compared with MPS.
Each applied reference standard thresholds of ≥ 70% stenosis for
diagnosing CAD, and avoided partial verification bias.
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Figure 9. Summary receiver operator curve plot of sensitivity versus specificity for performance of different
tests versus coronary angiography: Direct comparison MPS versus DSE. Each symbol represents a study, with
the height and width of each symbol being proportional to the inverse standard error of the sensitivity and
specificity respectively. The lines connecting paired MPS and DSE studies denote studies which investigated
the accuracy of MPS and DSE in the same study population (direct comparison)DSE: dobutamine stress
echocardiography; MPS: myocardial perfusion scintigraphy
20Cardiac testing for coronary artery disease in potential kidney transplant recipients (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 3 and Figure 6 summarise indirect comparison results.
Overall, there was evidence that DSE (13 studies) had better test
accuracy than MPS (9 studies) (P = 0.02). Using the results from
the earlier analysis, DSE appeared to have a higher pooled sensi-
tivity (DSE: 0.79 (95% CI 0.67 to 0.88) versus MPS: 0.74 (95%
CI 0.54 to 0.87) and specificity DSE: 0.89 (95% CI 0.81 to 0.94)
versus MPS: 0.70 (95% CI 0.51 to 0.84). The variability in ac-
curacy was smaller for DSE than MPS, demonstrated by the dif-
ference in size of the 95% confidence regions in HSROC space.
When we included only studies that used definitions of ≥ 70%
stenosis on coronary angiography to diagnose severe CAD, DSE
(9 studies) had pooled sensitivity and specificity of 0.76 (95% CI
0.60 to 0.87) and 0.88 (95% CI 0.78 to 0.94) respectively. MPS
(7 studies) had pooled sensitivity and specificity of 0.67 (95% CI
0.48 to 0.82) and 0.77 (95% CI 0.61 to 0.88) respectively. There
was no statistically significant difference between tests (P = 0.09)
(Figure 7). When we included only studies where partial verifi-
cation bias was avoided, DSE (10 studies) had pooled sensitivity
and specificity of 0.80 (95% CI 0.64 to 0.90) and 0.89 (95% CI
0.79 to 0.95) respectively. MPS (8 studies) had pooled sensitivity
and specificity of 0.68 (95% CI 0.51 to 0.81) and 0.75 (95%
CI 0.60 to 0.86) respectively. The difference in accuracy between
MPS and DSE tests for these studies was statistically significant (P
= 0.03) (Figure 8). When only studies that avoided partial verifi-
cation and had reference thresholds ≥ 70% stenosis on coronary
angiography were included in the analysis, there was no evidence
of a statistically significant difference between tests (P = 0.09).
DSE (8 studies) appeared to have a higher pooled sensitivity: 0.78
(95% CI 0.59 to 0.89) than MPS 0.67 (95% CI 0.48 to 0.82) and
DSE specificity: 0.88 (95% CI 0.76 to 0.94) versus 0.77 (95% CI
0.61 to 0.88)] compared with MPS (7 studies), as well as a higher
corresponding AUC.
Subgroup analyses
Sparse data, both in terms of numbers of studies and study par-
ticipants, meant that we were unable to perform meaningful sub-
group analyses on the effect of DM or prevalence of angina and
symptomatic ischaemic heart disease (IHD) on diagnostic test per-
formance. Only one study (Vandenberg 1996) included a patient
population who had no history of angina or IHD. Therefore, a
sensitivity analysis of diagnostic accuracy in studies that enrolled
only patients who had no symptoms of cardiac disease or history
of IHD could not be conducted.
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Summary of findings
Summary of results: Results of studies on cardiac testing in kidney transplant candidates
Review question: Comparison of non-invasive cardiac screening tests with coronary angiography for the detect ion of signif icant
CAD in potent ial kidney transplant recipients
Patient population: Kidney transplant candidates undergoing pre-transplant cardiac evaluat ion
Setting: Invest igat ions performed in hospital or in an outpat ient sett ing
Geographical location: Studies were conducted in USA (12 studies), Brazil (4 studies), India, (3 studies) the UK (3 studies),
Australia (1 study), Canada (1 study), and Spain (1 study)
Index test : Any non- or minimally invasive test used to assess risk of CAD
Reference standard: Coronary angiography
Included studies: DSE (13 studies; 745 part icipants), MPS (9 studies; 582 part icipants), EST (2 studies; 129 part icipants),
EBCT (1 study; 97 part icipants), DSF (1 study; 86 part icipants), exercise ventriculography (1 study; 35 part icipants), CIMT (1
study; 105 part icipants), rest ing wall motion abnormality on echocardiography (2 studies; 265 part icipants), lef t ventricular
dysfunct ion on echocardiography (1 study; 52 part icipants), m itral annular calcif icat ion on echocardiography (1 study; 125
part icipants), rest ing ECG (3 studies; 263 part icipants)
Limitations
Only DSE and MPS were evaluated in detail, although these also had only a lim ited number of included comparisons
with small sample sizes. No studies were found invest igat ing cardiopulmonary exercise test ing, CT coronary angiography,
magnetic resonance angiography or cardiac magnetic resonance imaging. Fewer than f ive studies were found for each of
EBCT, rest ing ECG, convent ional echocardiography, exercise ventriculography, DSF and CIMT. Sparse direct ly comparat ive
data also resulted in low power to detect important dif f erences in accuracy between tests
Signif icant heterogeneity was present among studies invest igat ing the same screening test. Although dif ferences in study
populat ion characterist ics (e.g. prevalence of chest pain) and test applicat ion (diagnost ic test threshold, criteria for posit ive
test, choice of stress agent and stress protocol, and operator variability) likely contributed to heterogeneity, we were
hindered f rom est imating their contribut ions because of relat ively sparse data, which resulted in low power
Part ial verif icat ion, where not all pat ients who received screening tests also received coronary angiography, occurred in 5/
25 comparisons. This may have af fected est imates of sensit ivity and specif icity
Two dif ferent reference standard thresholds (≥ 70% stenosis or ≥ 50% stenosis) were used in the included studies, with
most studies only using one reference standard threshold or the other. An overall analysis pooling the results of all studies
regardless of threshold may introduce addit ional heterogeneity due to a threshold ef fect
Results
Test DSE M PS
Number of studies [all studies] 13 9
Number of part icipants [all studies] 745 582
Pooled sensit ivity (95% CI) [all studies] 0.79 (0.67 to 0.88) 0.74 (0.54 to 0.87)
Pooled specif icity (95% CI) [all studies] 0.89 (0.81 to 0.94) 0.70 (0.51 to 0.84)
Number of studies [≥ 70% stenosis] 9 7
Number of part icipants [≥ 70%stenosis] 668 517
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Pooled sensit ivity (95%CI) [≥ 70%steno-
sis]
0.76 (0.60 to 0.87) 0.67 (0.48 to 0.82)
Pooled specif icity (95% CI) [≥ 70%
stenosis]
0.88 (0.78 to 0.94) 0.77 (0.61 to 0.88)
Number of false diagnoses of ≤ 70%
coronary artery stenosis in a standard
populat ion of 100 pat ients (false nega-
t ive rate)
24 (13 to 40)
per 100
33 (18 to 52)
per 100
Number of false diagnoses of ≥ 70%
coronary artery stenosis in a standard
populat ion of 1000 pat ients (false posi-
t ive rate)
12 (6 to 22)
per 100
23 (12 to 39)
per 100
Posit ive likelihood rat io [≥ 70%stenosis]
(95% CI)
6.44 (3.03 to 13.70) 2.89 (1.39 to 5.99)
Negative likelihood rat io [≥ 70% steno-
sis] (95% CI)
0.26 (0.13 to 0.50) 0.43 (0.23 to 0.80)
Post test probability af ter posit ive
screening test result for a pat ient with
low risk (10%to 29% pre test probability)
disease
42% to 72% 24% to 54%
Post test probability af ter posit ive
screening test result for a pat ient with
intermediate risk (30% to 59% pre test
probability) disease
73% to 90% 55% to 81%
Post test probability af ter posit ive
screening test result for a pat ient with
high risk (60% to 90% pre test probabil-
ity) disease
91% to 98% 81% to 96%
Post test probability af ter negat ive
screening test result for a pat ient with
low risk (10%to 29% pre test probability)
disease
3% to 10% 5% to 15%
Post test probability af ter negat ive
screening test result for a pat ient with
intermediate risk (30% to 59% pre test
probability) disease
10% to 27% 16% to 38%
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Post test probability af ter negat ive
screening test result for a pat ient with
high risk (60% to 90% pre test probabil-
ity) disease
28% to 70% 39% to 79%
Conclusions and comments
Both tests, especially DSE, have a role as triage tests for intermediate risk transplant candidates, with negat ive results
precluding the need for further evaluat ion with coronary angiography, thereby avoiding unnecessary risk to pat ients and
potent ially reducing healthcare costs
Given the wide heterogeneity in the est imates for both DSE and MPS, there is st ill considerable uncertainty in the true post-
test probabilit ies of each test
Current evidence suggests that, where feasible, DSE should be used as the screening invest igat ion of choice over MPS
Applicability of tests in clinical practice
Both DSE and MPS have a role as triage tests for the intermediate risk transplant candidates, with negat ive results reducing
the need for further evaluat ion with coronary angiography. In high risk pat ients, a posit ive non-invasive DSE or MPS conf irms
the high risk of severe CAD, but a negat ive result does not conclusively rule out severe CAD. In these pat ients, one may
consider proceeding immediately to coronary angiography and avoid using funct ional tests
The relat ively low sensit ivity and specif icity of both DSE and MPS however means that they are not perfect triage tests and
a signif icant number of pat ients will either have their signif icant CAD missed (false negat ives) or be referred in vain for
coronary angiography (false posit ive)
Despite the shortcomings of the non-invasive tests in their role as triage tests, the very select nature of the populat ion and
the unique challenges facing cardiac invest igat ion in this populat ion (part icularly, the need to avoid complicat ions arising
f rom an invasive gold standard) and the lack of an alternate better perform ing test means that we are forced to accept an
imperfect triage test
Funct ional test ing may provide addit ional prognost ic information, although an invest igat ion into this was not included under
the scope of this review.
Costs
None of the studies included a cost-ef fect iveness evaluat ion. MPS is known to be more expensive than DSE, although both
are less expensive than the reference standard, coronary angiography.
CAD - coronary artery disease; CI: conf idence interval; CIMT: carot id int imal medial thickness; DSE: Dobutamine stress
echocardiography; MPS: Myocardial perfusion scint igraphy
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D I S C U S S I O N
Summary of main results
Preliminary findings of comparisons of DSE and MPS versus
coronary angiography have been published by our review team
(Wang 2011), but this systematic review represents more index
tests and several studies that were since identified. Of the many
screening tests available, most studies investigated the accuracy of
DSE and MPS. Two systematic reviews were conducted that com-
pared DSE and MPS in the general population. These reviews re-
ported that MPS was more sensitive in detecting CAD, but exercise
stress echocardiography had higher specificity (Fleischmann 1998;
Schinkel 2003). Findings from our review indicate that DSE and
MPS have moderate levels of sensitivity and specificity to detect
severe coronary artery stenosis.
Our key findings are presented in Summary of findings. On di-
rect analysis, DSE had a higher point estimate of sensitivity and
specificity compared with MPS. This was statistically significant
for both the overall indirect comparison analysis (P = 0.02) and
the sensitivity analysis which included only studies that avoided
partial verification (P = 0.03). There was no statistical evidence
that DSE had higher diagnostic accuracy in the sensitivity anal-
ysis which included only studies that avoided partial verification
and had reference standard thresholds ≥ 70% stenosis (P = 0.09).
However, because results from studies that applied this common
threshold were similar to the overall analysis, the lack of statistical
significance may have resulted from a reduction of power due to
the smaller number of included studies. Although there were few
direct comparisons, in two studies that compared DSE and MPS
in the same population, DSE had a higher specificity and equiva-
lent or better sensitivity than MPS.
That DSE had a higher specificity than MPS is consistent with the
principle that reversible systolic dysfunction (detected by DSE)
usually occurs after reversible perfusion abnormalities (detected
by MPS). In the general population, MPS should have higher sen-
sitivity but lower specificity than stress echocardiography because
systolic dysfunction often occurs only when severe CAD is present.
Patients with ESKD often have hypertension, left ventricular hy-
pertrophy and decreased coronary flow reserve, all of which could
account for reduced specificity of MPS in kidney transplant can-
didates (Houghton 1990).
Causes of false negative results in MPS in the general population
include balanced triple vessel disease and submaximal heart rate
during stress. Although the reason for lower sensitivity in kidney
transplant candidates compared with the general population re-
mains unclear, differences in the effect of the stress agent drug
among patients with CKD and the general population offers a pos-
sible physiological reason for the difference in sensitivity. Dipyri-
damole, the drug routinely used in MPS, causes vasodilation of
coronary blood vessels by promoting accumulation of adenosine,
an endogenous vasodilator. Dipyridamole infusion leads to va-
sodilation of normal coronary arteries, which is interpreted as an
appropriate normal increase in cardiac perfusion. The decreased
perfusion resulting from reduced vasodilator response of diseased
vessels is interpreted as reversible ischaemia. A corresponding rise
in heart rate also generally occurs during dipyridamole infusion
and is thought to be secondary to vasodilatation, mediated in part
by the cardiac nerves. Heart transplant recipients have been shown
to have limited vasodilator response to dipyridamole, which has
been attributed to increased resting myocardial blood flow in the
transplanted heart resulting from increased cardiac workload and
cardiac de-innervation (Rechavia 1992). Similarly, patients with
CKD (particularly those who have diabetes) may also experience
a degree of functional de-innervation as part of an autonomic
neuropathy, which would potentially reduce the relative efficacy
of dipyridamole. CKD is also invariably associated with arterial
calcification and reduced coronary artery flow reserve (Niizuma
2008; Sezer 2007). This may also potentially lead to a decrease
in responsiveness to the vasodilating properties of dipyridamole.
On the other hand, dobutamine which is commonly used in stress
echocardiography, has direct inotropic effects on the cardiac my-
ocyte and potentially may be less affected by the mechanism de-
scribed.
There was also more variability in the spread of the MPS test results
in SROC space compared with DSE. This is probably because
MPS is a more subjective test. Several studies of MPS demonstrated
considerable inter- and intra-patient result variability, which may
limit its diagnostic utility (Akesson 2004; Burkhoff 2001). Vari-
ability was also observed in the DSE results, which may be due to
unevenness in local expertise to interpret test results across differ-
ent studies.
Significant heterogeneity was present, which could not be ex-
plained by differences in reference threshold and partial verifica-
tion. Clearly, other factors may have contributed to the clinical het-
erogeneity in the results. These include differences in study popu-
lation characteristics (such as prevalence of chest pain, prevalence
of diabetes) and test application (diagnostic test threshold, criteria
for positive test, choice of stress agent and stress protocol, and op-
erator variability). Limited data from the small numbers of studies
and participants meant that we were unable to perform subgroup
analyses of the effect of DM and prevalence of angina and IHD
on diagnostic performance. Other differences across studies may
also have played a role. One possible factor was sex of the partic-
ipants. One study (Gowdak 2010) showed that among patients
with diabetes, MPS test performance was influenced by the sex of
participants; sensitivity was lower in women (females 56%; males
65%). Accuracy data based on sex was not reported in any of the
included studies. Hence, we were unable to determine if the sex
of the participant influenced diagnostic accuracy.
Generally, methodological quality was poorly reported. Method-
ological quality scoring was based on published reports and addi-
tional data provided from correspondence with study authors. Un-
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clear reporting of certain methodological issues may not necessarily
indicate poor study design; restrictions imposed by journal word
limits, or editing, may have precluded reporting all QUADAS
items. Several methodological quality items were reported less fre-
quently than others. These included blinding of reference tests (7/
25 not reported), blinding of index tests (8/25 not reported), and
acceptable delay between tests (12/25 not reported). In addition
to the studies where blinding of reference and index tests was un-
certain, 3/25 studies reported no blinding of the reference stan-
dard; one study reported no blinding of the index test. Therefore,
lack of blinding may have affected our results; the overall effect of
unblinded reporting of reference and index tests is generally leads
to overestimation of diagnostic accuracy (Leeflang 2006).
We did not find any studies that investigated cardiopulmonary ex-
ercise testing, CT coronary angiography, magnetic resonance an-
giography or cardiac magnetic resonance imaging. Fewer than five
studies were found for each of EBCT, ECG, conventional echocar-
diography, exercise ventriculography, DSF and CIMT. This pre-
cluded any further meaningful comparisons other than that be-
tween DSE and MPS. DSF and exercise ventriculography are sel-
dom used for CAD screening. Nevertheless, results from studies
identified for this review (DSF: sensitivity 78%, specificity 66%;
exercise ventriculography: sensitivity 50%, specificity 67%) sug-
gest that neither DSF nor exercise ventriculography were likely
to be superior to DSE or MPS. EST appeared to have offer high
specificity (91%) but poor sensitivity (36%) in the one study
that included a sufficient number of participants (Sharma 2005).
Resting wall motion abnormality detected on traditional resting
transthoracic echocardiography was also found to offer high speci-
ficity (95% to 96%) but low sensitivity (31% to 33%). Mitral
annular calcification on echocardiography was studied in the same
population (Sharma 2005) and this had higher sensitivity (61%)
at the expense of lower specificity (72%). The marked variability
in sensitivity and specificity of resting ECG confirms that it has
no role in triaging patients for CAD. Notwithstanding the limita-
tions posed by few numbers of studies and participants presented,
EBCT and calcium scoring methods also appeared to have limited
utility in evaluating the cardiac health of potential kidney trans-
plant recipients. This is reflected in the fact that the optimal test
performance of EBCT in the only study identified (Rosario 2010)
was a calcium score of 1330.72, which is higher than the usual
threshold used in the general population. There is also a theoret-
ical disadvantage of calcium scoring methods in potential kidney
transplant recipients due to the increased prevalence of arterial
calcification in patients with CKD, arising from metabolic bone
disease. Although published studies were not identified in this re-
view, other tests that might be expected to have limited application
in the pre-transplant setting for patients with CKD include CT
coronary angiography (exposure to nephrotoxic IV contrast that
could adversely affect any residual kidney function) and magnetic
resonance imaging (MRI) or angiography (risk of gadolinium in-
duced nephrogenic systemic fibrosis).
Strengths and weaknesses of the review
A strength of this review was the sensitive electronic search strategy
developed that identified both published and unpublished stud-
ies. Our search strategy excluded search filters for diagnostic terms
because they have limited utility (Leeflang 2006; Ritchie 2007).
Other strengths included our analytic approach of combining re-
sults from studies with similar methodological characteristics and
applying the HSROC model to conduct our analysis. The hier-
archical modelling strategy accounted for sampling variability in
estimates of sensitivity and specificity (and their correlations) in
each study when estimating the random effects. This resulted in
accuracy estimates that provided better assessments of underlying
common log odds ratios (Macaskill 2003). To ensure that findings
were generalisable, we included only studies that investigated only
potential kidney transplant recipients. We excluded studies that
enrolled participants with ESKD because it could be reasonably
anticipated that inclusion of unselected dialysis patients would
modify expected differences in underlying prevalence of CAD,
and the presence and severity of other comorbidities, as well as
differences in clinical rationales for testing. By concentrating on
potential transplant candidates our findings may not be general-
isable to dialysis or CKD patients who would not benefit from
transplantation. Our vigilance in contacting authors to obtain data
missing or not reported in studies was rewarded by a satisfying
number of responses.
Significant heterogeneity was present among studies that investi-
gated the same screening test. Given that underlying prevalence
of disease in a population has potential to alter diagnostic perfor-
mance (Leeflang 2009), knowledge of the effect of clinical char-
acteristics such as angina or diabetes on diagnostic performance
would enable better informed decisions about screening and in-
terpretation of results. Although differences in study population
characteristics, such as prevalence of chest pain, and test appli-
cation (diagnostic test threshold, criteria for positive test, choice
of stress agent and stress protocol, and operator variability) were
likely to have contributed to heterogeneity, we were hindered in
estimating their contributions because of data paucity, which re-
sulted in low power. Consequently, we were unable to derive sum-
mary measures of diagnostic performance for specific patient sub-
groups. Data that were directly comparative were limited and also
resulted in low power to detect important differences in accuracy
among tests. Incomplete reporting of baseline characteristics and
study design features that are necessary for scoring methodological
quality was a further limitation that was resolved by contacting
study authors to obtain additional data.
Applicability of findings to the review question
Current guidelines for preoperative cardiac evaluation of trans-
plant candidates are unclear about the optimal method of assess-
ment for potential kidney transplant recipients. Patients are often
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referred for coronary angiography as a result of a positive non-in-
vasive screening test or deemed to be at high risk of CAD. Non-in-
vasive functional tests, such as DSE or MPS, have been used in the
general population as a method of triaging patients for coronary
angiography. Results from our review provide a base to inform
clinical decision making that were derived from studies conducted
in relevant populations. Table 4 summarises test performance for
transplant candidates relative to the general population.
Figure 10 illustrates the applicability of our findings to clinical
practice. Patients in the general population who present with sta-
ble chest pain for assessment are typically assigned pre-test prob-
abilities of significant CAD of 10% to 29% (low risk), 30% to
59% (intermediate risk) or 60% to 90% (high risk) determined
using risk tables (NICE Clinical Guideline 1995). Given the wide
heterogeneity in the estimates for both DSE and MPS, there is
considerable uncertainty in the true post-test probabilities of each
test. However, using the summary estimates in this review, both
DSE and MPS may prove useful in ruling out CAD in patients
considered to be at low risk for the condition. Patients with pos-
itive stress test results warrant additional investigation with coro-
nary angiography. However, the true discriminating value of both
tests (especially DSE) is in detecting CAD in intermediate risk
patients - a category that includes many potential kidney trans-
plant recipients. Both tests help to classify patients at intermediate
risk into either high or low risk categories. When DSE was used,
patients at intermediate risk of CAD who tested positive had post-
test probability of 73% to 90% (high risk) and those who tested
negative were downgraded to low risk (10% to 27%). Both tests,
but especially DSE, have roles as triage tests for intermediate risk
transplant candidates; negative results can reduce the need for fur-
ther evaluation with coronary angiography. In high risk patients,
a positive non-invasive DSE or MPS test result confirms the high
risk of severe CAD, but a negative result does not conclusively
rule out severe CAD. These patients can be managed by being
referred for coronary angiography, thus avoiding functional tests.
Nevertheless, functional testing may provide additional prognos-
tic information, or help to prioritise patients waiting to be referred
for coronary angiography in resource-limited areas.
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Figure 10. †Based on the positive and negative likelihood ratios calculated from the systematic review in
studies which avoided partial verification and used a reference standard threshold of ≥70% stenosis. DSE had a
positive likelihood ratio of 6.44 (95% CI 3.03 to 13.70) and negative likelihood ratio of 0.26 (95% CI 0.13 to
0.50). MPS had a positive likelihood ratio of 2.89 (95% CI 1.39 to 5.99) and negative likelihood ratio of 0.43 (95%
CI 0.23 to 0.80).
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DSE and MPS are not perfect triage tests and a significant num-
ber of patients will either have their significant CAD missed (false
negatives) or be referred unnecessarily for coronary angiography
(false positives). Furthermore, the imprecision of the likelihood
ratios resulting from significant between-study heterogeneity pro-
duces significant uncertainty in the post-test probabilities for both
positive and negative tests. A negative DSE test would still, in a
low risk population, yield a post-test probability of 10% to 27%.
However, both the desire to avoid complications arising from rou-
tine referral of such patients to an invasive gold standard investiga-
tions, and the lack of a more accurate alternative method of screen-
ing may or may not convince clinicians to consider such posterior
test probabilities to be sufficiently low to excuse an asymptomatic
individual from having further invasive investigation.
Our results need to be considered together with the real world
limitations of practising medicine. Despite the apparent superi-
ority of DSE over MPS to detect severe CAD, the interaction of
many clinical factors often result in different transplant centres
preferring one screening test over another. These factors may be
institutional, arising from practicalities such as availability and or
expertise of one screening modality, but not both, in a transplant
centre; or patient-related issues such as lack of cardiorespiratory
fitness or mobility for exercise stress testing. DSE requires IV in-
fusion and is not available in all cardiology departments. Many
cardiology practices offer exercise stress echocardiography, but we
were unable to identify any studies of exercise stress echocardio-
graphy in potential kidney transplant recipients. The diagnostic
accuracy of exercise stress echocardiography is likely to be sim-
ilar to DSE, although there is a higher chance of submaximal,
and therefore uninterpretable, stress test results in patients who
undergo this test. The patient factors that affect physician choice
of screening test are less likely to be an issue in a population of
potential kidney transplant recipients compared with people who
are not transplantation candidates, given that transplantation can-
didates represent a selected healthier subpopulation of those with
CKD. MPS requires the presence of a nuclear medicine depart-
ment. Although these departments are found in tertiary referral
hospitals, they may not be present in smaller hospitals or resource-
poor settings.
For this review, we defined coronary artery stenosis as ≥ 50%
stenosis, and severe coronary artery stenosis as ≥ 70% steno-
sis. Although asymptomatic patients with certain high risk coro-
nary lesions (e.g. left main or equivalent disease, and triple vessel
CAD, particularly with left ventricular dysfunction) benefit from
revascularisation regardless of symptoms (Eagle 2004), the bene-
fit of preoperative revascularisation before transplant surgery re-
mains questionable. Two RCTs (CARP (McFalls 2004) and DE-
CREASE-V (Poldermans 2007)) did not demonstrate any revas-
cularisation benefit in asymptomatic CAD before major vascu-
lar surgery. Nevertheless, the diagnosis of angiographically-proven
significant CAD in kidney transplant candidates imposes further
implications on patient management. These include consideration
of need for perioperative beta blockade, antiplatelet agents and an-
ticoagulation. A recent registry study (De Lima 2010) confirmed
that in patients with CKD and significant CAD, medical therapy
results in adequate long-term event-free survival. However, in this
study, a greater cardiac event rate occurred in patients who ful-
filled criteria for revascularisation but declined intervention. Nev-
ertheless, the lack of RCTs specifically addressing this question in
kidney transplant settings means that uncertainty remains about
if failure to perform coronary intervention when necessary results
in an accentuated increased risk of adverse events and death.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Of the non-invasive screening tests available to detect CAD in
potential kidney transplant candidates, MPS and DSE have been
studied in detail. Both tests, especially DSE, have roles as triage
tests for transplant candidates with intermediate of CAD. Nega-
tive DSE results preclude need for further evaluation using coro-
nary angiography, avoiding unnecessary risk to patients and po-
tentially reducing healthcare costs. Given the wide heterogeneity
in the estimates for both DSE and MPS, considerable uncertainty
remains concerning the true post-test probabilities of each test.
Current evidence suggests that where feasible DSE should be used
as the screening investigation of choice.
Implications for research
The ability to identify patients at high risk of CAD may not nec-
essarily enable clinicians to predict cardiac event-free survival fol-
lowing transplantation. In the postoperative period, other factors
such as inflammation, sympathetic nervous system activation, hy-
percoagulability and hypoxia contribute to increased cardiac mor-
bidity and mortality (Yao 2004). Patients with kidney disease have
abnormal coronary microcirculation and reduced coronary flow
reserve, which may result in cardiac ischaemic events, even in the
absence of macrovascular stenoses (Caliskan 2008; Niizuma 2008;
Sezer 2007). Future research examining the ability of functional
tests to predict postoperative outcome is urgently needed.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bates 1996
Clinical features and settings Clinical features
• Adult patients who developed insulin dependent DM aged ≤ 25 years and
underwent DSE before planned kidney or kidney-pancreas transplantation between
January 1989 and July 1993.
Setting
• University Hospital, Indianapolis, Indiana, USA.
Participants • Number: 53 patients had preoperative screening; 17 received both DSE and
coronary angiography
• DM: 100%
• Angina pectoris: Not reported
• Hypertension: 98%
• Sex: 64% male
Study design Prospective, cohort study
Target condition and reference standard(s) CAD on coronary angiography
• defined by ≥ 50% stenosis
Index and comparator tests DSE
• Regional wall motion was graded as normal, hypokinetic, akinetic, or dyskinetic
using a 16-segment model at rest, low dose, peak dose, and recovery stages, and assigned
a coronary vascular distribution. A study was considered abnormal if a wall motion
abnormality involving ≥ 2 segments was present at rest or developed during stress.
Follow-up Patients were followed-up for a mean of 498 ± 425 days (range 2 to 1269) after trans-
plantation
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Adult patients with insulin-dependent DM
being considered for kidney and/or kidney-
pancreas transplantation
Acceptable reference standard?
All tests
Yes Coronary angiography with a reference
standard threshold ≥ 50% stenosis
Acceptable delay between tests?
All tests
No 18 patients underwent cardiac catheterisa-
tion within 101 ± 263 days (range = 200
days before to 557 days after) of DSE. In-
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Bates 1996 (Continued)
terval progression of CAD is possible
Partial verification avoided?
All tests
No 18/53 patients underwent coronary an-
giography.
Differential verification avoided?
All tests
Yes Disease status (CAD) diagnosed by coro-
nary angiography.
Incorporation avoided?
All tests
Yes Disease status (CAD) diagnosed by coro-
nary angiography.
Reference standard results blinded?
All tests
Yes All available catheterisation studies were in-
terpreted by a blinded, experienced angiog-
rapher using digital callipers
Index test results blinded?
All tests
Yes All studies were interpreted by an expe-
rienced echocardiographer blinded to the
clinical and stress electrocardiogram data
Relevant clinical information?
All tests
Yes Relevant clinical information was provided
regarding the performance and analysis of
both the index and reference tests
Uninterpretable results reported?
All tests
Yes No results were reported to be uninter-
pretable.
Withdrawals explained?
All tests
Yes All patients missing from the final analysis
were accounted for
Bennett 1978
Clinical features and settings Clinical features
• Patients with juvenile insulin-dependent DM and ESKD who presented for
kidney transplant cardiac evaluation. Eleven patients with evidence of arteriosclerotic
heart disease gave their informed consent for coronary arteriogram and left ventricular
angiogram. Seven patients had EST.
Setting
• University of Oregon Health Sciences Center, Oregon, USA
Participants • Number: 4 participants
• DM: 100%
• Angina pectoris: percentage of patients with angina not reported
• Hypertension:, 100%
• Sex: 36% male
Study design Cohort study
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Bennett 1978 (Continued)
Target condition and reference standard(s) Coronary artery stenosis measured by coronary angiography
• Absolute degree of stenosis recorded for each patient.
Index and comparator tests EST
Follow-up 30-38 months, unless death occurred earlier.
Notes Three of the seven patients had a non-diagnostic stress test due to inadequate rate as a
result of fatigue
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Patients with juvenile insulin-dependent
DM and ESKD who presented for kidney
transplant cardiac evaluation
Acceptable reference standard?
All tests
Yes Coronary artery stenosis measured by
coronary angiography. Absolute degree of
stenosis recorded for each patient
Acceptable delay between tests?
All tests
Unclear Unclear, but likely to be only short delay
between tests.
Partial verification avoided?
All tests
Yes All patients received angiography.
Differential verification avoided?
All tests
Yes This was not an issue in this study. Disease
status (CAD) is diagnosed only through
coronary angiography
Incorporation avoided?
All tests
Yes This was not an issue in this study. Disease
status (CAD) is diagnosed only through
coronary angiography
Reference standard results blinded?
All tests
Unclear Not reported.
Index test results blinded?
All tests
Unclear Not reported.
Relevant clinical information?
All tests
Yes Relevant clinical information was provided
regarding the performance and analysis of
both the index and reference tests
Uninterpretable results reported?
All tests
Yes No results were reported to be uninter-
pretable.
39Cardiac testing for coronary artery disease in potential kidney transplant recipients (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Bennett 1978 (Continued)
Withdrawals explained?
All tests
Yes All patients missing from the final analysis
were accounted for
Boudreau 1990
Clinical features and settings Clinical features
• Patients with DM type 1 and ESKD who presented for kidney transplant
evaluation
Setting
• University of Minnesota Hospital and Clinics, Minnesota, USA
Participants • Number: 80
• DM type 1: 100%
• Angina pectoris: 12.5% patients had history of myocardial infarction
• Hypertension: Not reported
• Sex: 64% male
Study design Cross sectional study.
Target condition and reference standard(s) Coronary artery stenosis measured by coronary angiography
• Coronary angiograms were analysed by a blinded observer who was unaware of
thallium scan results or the patient’s history. Quantitative analysis sought to determine
the percentage of cross sectional narrowing and absolute cross sectional diameter. The
criterion for positive test results was ≥ 70% reduction in cross sectional area.
Index and comparator tests Dipyridamole-Tl-201 scintigraphy MPS (40 oral, 40 IV dipyridamole)
• Scans interpreted by consensus of three experienced radiologists who were
unaware of angiography results or patient history. Each view was subdivided into five
segments, and the stress views (first set of images) examined for areas of reduced
activity. Categorisation as ’indeterminate’ was not permitted. Stress segments classified
as abnormal were examined for definite, possible, or absent redistribution. Other
categories were ’positive’ and ’fixed defect’. Mixed defects were defined as areas of
partial redistribution in a fixed defect or fixed defects in association with reversible
defects. Quantitative analysis, including count profiles and washout rates, was also
performed. However, only qualitative results were used to reach the final diagnosis,
since normal quantitative values are unavailable for this test in this patient population.
Follow-up None.
Notes Patients were reported as being followed-up long-term to assess the risk factors (including
the thallium scan) for cardiac events after kidney transplantation, although no published
data were available
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
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Boudreau 1990 (Continued)
Representative spectrum?
All tests
Yes Patients with type 1 DM and ESKD who
presented for kidney transplant evaluation
Acceptable reference standard?
All tests
Yes Coronary angiography with a reference
standard threshold of ≥ 70% stenosis
Acceptable delay between tests?
All tests
Unclear Likely to be a short delay between tests.
Partial verification avoided?
All tests
Yes All participants who underwent the index
test also received the reference standard test
Differential verification avoided?
All tests
Yes Disease status (CAD) diagnosed by coro-
nary angiography.
Incorporation avoided?
All tests
Yes Disease status (CAD) diagnosed by coro-
nary angiography.
Reference standard results blinded?
All tests
Yes Coronary angiograms were analysed by a
blinded observer (not the person who per-
formed the angiography) who was unaware
of the Tl-201 scan results or the patient’s
history
Index test results blinded?
All tests
Yes The scans were interpreted by consensus
of three experienced radiologists who were
unaware of the angiography results or pa-
tient history
Relevant clinical information?
All tests
Yes Relevant clinical information was provided
regarding the performance and analysis of
both the index and reference tests
Uninterpretable results reported?
All tests
Yes No results were reported to be uninter-
pretable.
Withdrawals explained?
All tests
Yes No missing patients.
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Brennan 1997
Clinical features and settings Clinical features
• Patients with ESKD at risk of CAD who presented for kidney transplant cardiac
evaluation
Setting
• Washington University and Barnes-Jewish Hospital, St. Louis, Missouri, USA
Participants • Number: 47
• DM: 56%
• Hypertension: 90%
• Sex: 45% male
• Mean age: 51 years
• History of smoking: 61%
• Hypercholesterolaemia: 15%
• Coronary heart failure: 2%
• Clinical evidence CAD: 21%
Study design Cohort study
Target condition and reference standard(s) Coronary artery stenosis measured by coronary angiography
• The criterion for positive test results was ≥ 50% reduction in cross sectional area.
Index and comparator tests DSE
• Two-dimensional echocardiography as part of pretransplant evaluation. Graded
infusions of dobutamine were administered (5 to 40 mg/kg/min) until the maximum
predicted heart rate was achieved. If needed, IV atropine (0.4 to 2.0 mg) was given to
increase heart rate to ~85% of the maximum predicted heart rate. The test was
terminated if patients developed: significant arrhythmia, severe hypertension or
hypotension, or had new or worsening baseline segmental wall motion abnormalities in
≥ 2 major coronary perfusion regions. Segmental wall motion was scored according to
American Society of Echocardiography recommendations, using lh-segment model.
Each segment was graded using a semi-quantitative scoring system (normal or
hyperdynamic (1); hypokinesis (2); akinesis (3); dyskinesis (4)). The wall motion score
index was derived as an average of the 16 segments. All studies were reviewed
independently by 2 experienced echocardiographers who were blinded to the clinical
data.
Follow-up Follow-up (range 3 to 64 months) data were obtained for all 47 participants
Notes Of the 47 patients who underwent DSE, all 5 patients who tested positive received
coronary angiography. Seven other patients who had negative DSE received coronary
angiography. The decision about providing coronary angiography for those who were
index test negative was not made on grounds of clinical or high pre-test suspicion (author
correspondence)
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
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Brennan 1997 (Continued)
Representative spectrum?
All tests
Yes Patients with ESKD at risk of CAD who
presented for kidney transplant cardiac
evaluation
Acceptable reference standard?
All tests
Yes Coronary angiography with a reference
standard threshold of ≥ 50% stenosis
Acceptable delay between tests?
All tests
Yes Average time from DSE to coronary an-
giography < 9 months (author correspon-
dence)
Partial verification avoided?
All tests
No Of the 47 patients who underwent DSE,
5 who tested positive underwent coronary
angiography, and 7 others who had nega-
tive DSE results also underwent coronary
angiography. The reason that patients who
were index test negative underwent coro-
nary angiography was for other than clini-
cal or high pre-test suspicion (author cor-
respondence)
Differential verification avoided?
All tests
Yes Disease status (CAD) diagnosed by coro-
nary angiography.
Incorporation avoided?
All tests
Yes Disease status (CAD) diagnosed by coro-
nary angiography.
Reference standard results blinded?
All tests
No It is probable that the person who per-
formed the coronary angiogram was aware
of the DSE result. However, because later
coronary angiograms were performed by an
outside institution, this was not necessarily
the case (author correspondence)
Index test results blinded?
All tests
Yes All studies were reviewed independently by
two experienced echocardiographers who
were blinded to the clinical data
Relevant clinical information?
All tests
Yes Relevant clinical information was provided
regarding the performance and analysis of
both the index and reference tests
Uninterpretable results reported?
All tests
Yes No results were reported to be uninter-
pretable.
Withdrawals explained?
All tests
Yes All patients missing from the final analysis
were accounted for
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Cai 2010
Clinical features and settings Clinical features
• Patients with ESKD and intermediate to high risk of CAD awaiting kidney
transplantation. CAD defined as presence of at least 1 of: age > 50 years, DM, previous
MI or stroke, or extracardiac atherosclerosis
Setting
• Geisinger Medical Center, Danville, Pennsylvania, USA
Participants Patients at intermediate to high risk of CAD underwent DSE 1 to 12 months (median
5 months) before kidney transplantation
• Number: 38
• DM: 54%
• Angina pectoris: percentage not reported
• Hypertension: 86%
• Sex: 64% male
Study design Retrospective cohort study.
Target condition and reference standard(s) Coronary artery stenosis measured by coronary angiography
• The criterion for positive test results was ≥ 70% reduction in cross sectional area.
Index and comparator tests DSE
• Performed according to a standard dobutamine-atropine protocol and included
complete resting echo-Doppler cardiography. Incremental doses of dobutamine (5 to
50 mg/kg/min) infused at 3 minute intervals. If the target (85% predicted maximum
for age) heart rate was not reached, and in the absence of inducible ischaemia, 0.25 mg
IV atropine administered up to a maximum dose of 1 mg. Echocardiographic images
were obtained in the standardised parasternal long- and short-axes (midventricular and
apical), and in apical 2-, 3-, 4-, and 5-chamber views at each stage, and were stored
digitally. DSE end points were defined as development of new or worsening wall
motion abnormality (ischaemia), achievement of > 85% of the predicted maximum
heart rate for age, severe symptoms of angina or dyspnoea, SBP < 85 mm Hg or > 220
mm Hg or a decrease in SBP > 20 mm Hg from one stage to the next, > 2 mV ST
segment depression in at least 2 consecutive leads, or significant arrhythmias (non-
sustained/sustained ventricular/supraventricular tachycardia or high-grade
atrioventricular block).
Follow-up Patients were followed up for a mean of 60 months (range 3 to 145 months) after DSE.
The time from kidney transplant to follow-up was 1 to 135 months (median 49 months)
Notes For the purpose of the analysis, only inducible wall motion abnormalities were counted
as positive DSE
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Patients with ESKD and intermediate to
high risk of CAD awaiting kidney trans-
plantation
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Cai 2010 (Continued)
Acceptable reference standard?
All tests
Yes Coronary angiography with a reference
standard threshold of ≥ 70% stenosis
Acceptable delay between tests?
All tests
Unclear Likely to be short delay between tests.
Partial verification avoided?
All tests
No 38 patients (23 with and 15 without in-
ducible ischaemia on DSE) underwent
coronary angiography after DSE
Differential verification avoided?
All tests
Yes Disease status (CAD) diagnosed by coro-
nary angiography.
Incorporation avoided?
All tests
Yes Disease status (CAD) diagnosed by coro-
nary angiography.
Reference standard results blinded?
All tests
Unclear Not reported.
Index test results blinded?
All tests
Unclear Not reported.
Relevant clinical information?
All tests
Yes Relevant clinical information was provided
regarding the performance and analysis of
both the index and reference tests
Uninterpretable results reported?
All tests
Yes No results were reported to be uninter-
pretable.
Withdrawals explained?
All tests
Yes All patients missing from the final analysis
were accounted for
De Lima 2003
Clinical features and settings Clinical features
• Patients presenting for pre-transplant cardiac evaluation based on the presence of
at least one of the following characteristics: age > 50 years, DM, angina, previous MI or
stroke, left ventricular dysfunction, and extracardiac atherosclerosis. Subjects without
these characteristics were not studied because they have a low frequency of coronary
events.
Setting
• Hospital das Clínicas, University of São Paulo Medical School, Brazil
Participants • Number: 150 (data from 24 participants excluded: lost to follow-up (5); declined
to continue (19))
• DM: 30%
• Angina pectoris: 25%
• Hypertension: 95%
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De Lima 2003 (Continued)
• Sex: 77% male
Study design Cohort study.
Target condition and reference standard(s) Coronary artery stenosis measured by coronary angiography
• The criterion for positive test results was ≥ 70% reduction in cross sectional area.
Invasive and non-invasive testing were analysed independently by 2 experts in the
respective methods without previous knowledge of the experimental hypothesis.
Disagreement was arbitrated by a third expert.
Index and comparator tests DSE
• Stepwise infusion of dobutamine was started at 5 µg/kg/min and increased to 40
µg/kg/min in 3 minute stages. Inducible ischaemia was defined as hypokinesis or as
accentuation of the degree of baseline hypokinesis during the infusion. The test was
interrupted if SBP or DBP surpassed 220 mm Hg and 120 mm Hg, respectively, or
when SBP fell below 90 mm Hg.
• Dipyridamole stress testing (single photon emission-computed tomography with
technecium-99m methoxyisobutylisonitrite)
◦ Stress was induced by dipyridamole (0.5 mg/kg IV). Fixed perfusion defects
were interpreted as evidence of fibrosis; transient hypoperfusion was interpreted as
ischaemia.
Follow-up Five participants were lost to follow-up. Minimum and mean follow-up periods were
6 and 26 months, respectively. The outcome measure was cardiac events, predefined
as sudden death, MI, life-threatening arrhythmia, heart failure, pulmonary oedema,
unstable angina, and myocardial revascularisation
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Kidney transplantation candidates as part
of cardiac evaluation
Acceptable reference standard?
All tests
Yes Coronary angiography with a reference
standard threshold of ≥ 70% stenosis
Acceptable delay between tests?
All tests
Yes Interval between tests was 2 to 6 weeks (au-
thor correspondence)
Partial verification avoided?
All tests
Yes All participants who underwent an index
test also received the reference standard test
Differential verification avoided?
All tests
Yes Disease status (CAD) diagnosed by coro-
nary angiography.
46Cardiac testing for coronary artery disease in potential kidney transplant recipients (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
De Lima 2003 (Continued)
Incorporation avoided?
All tests
Yes Disease status (CAD) diagnosed by coro-
nary angiography.
Reference standard results blinded?
All tests
No No blinding for outcomes assessment.
Index test results blinded?
All tests
No No blinding for outcomes assessment.
Relevant clinical information?
All tests
Yes Relevant clinical information was provided
regarding the performance and analysis of
both the index and reference tests
Uninterpretable results reported?
All tests
Yes The number of tests that were submaximal
were reported.
Withdrawals explained?
All tests
Yes All patients missing from the final analysis
were accounted for
Ferreira 2007
Clinical features and settings Clinical features
• Kidney transplant candidates with diabetic kidney disease or other causes of CKD
or ESKD undergoing cardiac evaluation. Examinations performed one day after
haemodialysis.
Setting
• Universidade Federal de São Paulo, Escola Paulista de Medicina, Hospital do Rim
e Hipertensão e Hospital São Paulo, Brazil
Participants • Aged > 40 years, who presented with ≥ 2 risk factors
• Number: 126 participants
• DM: 27%
• Angina pectoris: 12%
• Hypertension: not reported
• Sex: 69% male
Exclusion criteria
• Previous history of MI or surgical or percutaneous myocardial revascularization;
unstable angina; decompensated CHF; significant aortic stenosis; pulmonary HTN;
hypertrophic cardiomyopathy; inadequate echocardiographic window; atropine use
restrictions (glaucoma and obstructive uropathy); irregular dialysis regimen.
Study design Cross sectional study.
Target condition and reference standard(s) Coronary artery stenosis measured by coronary angiography
• The criterion for positive test results was ≥70% reduction in cross-sectional area.
47Cardiac testing for coronary artery disease in potential kidney transplant recipients (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Ferreira 2007 (Continued)
Index and comparator tests Dobutamine/atropine stress echocardiography
• Progressive doses of dobutamine 5, 10, 20, 30 and 40 µg/kg/min, with an
increment every 3 minutes. In cases when the final objective of the evaluation had not
been reached, 0.25 mg/min atropine was added simultaneously after the third minute
of the infusion of 40 µg/kg/min of dobutamine, up to a total maximum cumulative
dose of 1 mg. The test was considered diagnostic when either 85% of the maximum for
age or echocardiographic signs of myocardial ischaemia was reached. The test was
considered non-diagnostic when there were inadequate images for the analysis (lack of
definition on ≥ 2 myocardial segments); inability to reach target stress, and premature
test withdrawal due to limiting side effects without attaining one of the test aims.
• Definitions guiding interpretation were: Normal result defined as uniform
increase of systolic movement and thickening of the left ventricular wall and
consequent reduction of its final systolic volume (global hyperdynamic response); a
positive result for myocardial ischaemia was defined as a new alteration of the reversible
segmental contractility or worsening of a pre-existing segmental alteration, in ≥ 2
contiguous myocardial segments.
Follow-up
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Patients with ESKD who were kidney
transplant candidates undergoing cardiac
evaluation. Examinations performed one
day after haemodialysis
Acceptable reference standard?
All tests
Yes Coronary angiography with a reference
standard threshold of ≥ 70% stenosis
Acceptable delay between tests?
All tests
Yes Not longer than 2 months.
Partial verification avoided?
All tests
Yes All participants who underwent an index
test also received the reference standard test
Differential verification avoided?
All tests
Yes This was not an issue in this study. Disease
status (CAD) is diagnosed only through
coronary angiography
Incorporation avoided?
All tests
Yes This was not an issue in this study. Disease
status (CAD) is diagnosed only through
coronary angiography
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Ferreira 2007 (Continued)
Reference standard results blinded?
All tests
Yes The measurement bias was controlled
through the “blind” interpretation of the
test regarding the coronary angiography,
which was considered the reference stan-
dard
Index test results blinded?
All tests
Yes The recorded images were later interpreted
by two members who were blinded to the
patients’ clinical data, as independent ob-
servers. The discordance was solved by con-
sensus between the two observers
Relevant clinical information?
All tests
Yes Relevant clinical information was provided
regarding the performance and analysis of
both the index and reference tests
Uninterpretable results reported?
All tests
Yes Of 148 patients submitted to the test, 135
finished the protocol, which corresponds to
a feasibility of 91%. The reasons that led
to test interruption were: attaining 85% of
maximum CF for age: 121 (81%); limiting
side effects: 13 (9%); echocardiographic
signs of ischaemia: 10 (7%) and end of the
protocol: 4 (3%)
Withdrawals explained?
All tests
Yes Thirteen patients presented an early with-
drawal of the protocol due to limiting side
effects: 12 (8.5%) due to hypertensive re-
sponse and 1 (0.5%) due to severe angina
Gang 2007
Clinical features and settings Clinical features
• Patients with DM and ESKD who presented for kidney transplant cardiac
evaluation
Setting
• Muljibhai Patel Urological Hospital, Gujarat, India
Participants • Number: 40
• Type 2 DM: 100%
• ESKD: 100%
• Angina pectoris: 5%
• Hypertension: 92%
• Sex: 90% male
Study design Cross sectional study.
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Gang 2007 (Continued)
Target condition and reference standard(s) Coronary artery stenosis measured by coronary angiography
• Criterion for positive test results was ≥70% reduction in cross sectional area
Index and comparator tests DSE
• DSE was performed by recording images in standard parasternal long- and short-
axis and apical 4 chamber and 2 chamber views at baseline, and during stepwise
infusion of dobutamine in 3 minute stages at 5, 10, 20, 30 and 40 µg/kg/min.
Atropine was administered as needed. DSE end points were target heart rate achieved
([220-age]x0.85), maximum drug dose, intolerable angina, new inducible regional wall
motion abnormalities in ≥ 2 coronary vascular territories, ventricular tachycardia,
supraventricular tachycardia, hypotension and SBP > 240 mm Hg.
Resting ECG
• Abnormal ECG findings included evidence of left ventricular hypertrophy by
voltage criteria (8 patients), evidence of underlying ischaemia, or left bundle branch
block.
Follow-up None
Notes • Patients underwent DSE followed by coronary angiography as a part of kidney
transplant evaluation.
• Resting ECG was discounted from the analysis as “abnormal ECG”. This was a
heterogeneous concept that was suggestive of both ischaemic and non-ischaemic (such
as left ventricular hypertrophy) results. 12/40 patients (30%) had baseline ECG
evidence of left ventricular hypertrophy by voltage criteria, 8 (20%) patients had
evidence of underlying ischaemia; one patient (4%) had left bundle branch block. 19
patients had normal ECGs. 9/21 patients whose ECGs were abnormal had significant
CAD on angiography.
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Patients with DM and ESKD who pre-
sented for kidney transplant cardiac evalu-
ation
Acceptable reference standard?
All tests
Yes Coronary angiography with a reference
standard threshold of ≥ 70% stenosis
Acceptable delay between tests?
All tests
Yes DSE and coronary angiography were per-
formed within the same week (author cor-
respondence)
Partial verification avoided?
All tests
Yes All participants who underwent an index
test also received the reference standard test
Differential verification avoided?
All tests
Yes Disease status (CAD) diagnosed by coro-
nary angiography.
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Gang 2007 (Continued)
Incorporation avoided?
All tests
Yes Disease status (CAD) diagnosed by coro-
nary angiography.
Reference standard results blinded?
All tests
No The person who interpreted the coronary
angiogram reports was not blinded to DSE
results (author correspondence)
Index test results blinded?
All tests
Unclear All coronary angiograms were performed
after DSE, so index tests were likely to be
performed without influence from the ref-
erence standard
Relevant clinical information?
All tests
Yes Relevant clinical information was provided
regarding the performance and analysis of
both the index and reference tests
Uninterpretable results reported?
All tests
Yes No results were reported to be uninter-
pretable.
Withdrawals explained?
All tests
Yes No withdrawals reported.
Garcia-Canton 1998
Clinical features and settings Clinical features
• Patients who presented for cardiac evaluation before kidney transplantation
underwent DSE and MPS followed by coronary angiography
Setting
• Hospital Universitario Insular de Gran Canaria, Spain
Participants • Number: 27
• DM: percentage not reported
• ESKD: percentage not reported
• Angina pectoris: percentage not reported
• Hypertension: percentage not reported
• Sex: 67% male
Study design Cross sectional study
Target condition and reference standard(s) Coronary artery stenosis measured by coronary angiography
• Criterion for positive test results was ≥ 70% reduction in cross sectional area.
Index and comparator tests DSE
• Stress 99M-Technetium methoxyisobutylisonitrile SPECT
Follow-up None reported.
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Garcia-Canton 1998 (Continued)
Notes Conference presentation. Unpublished as a study. Additional information obtained from
correspondence with authors
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Patients who presented for cardiac evalua-
tion before kidney transplantation
Acceptable reference standard?
All tests
Yes Coronary angiography with a reference
standard threshold of ≥ 70% stenosis
Acceptable delay between tests?
All tests
Yes All coronary angiography was performed
from two weeks to three months after the
other tests (author correspondence)
Partial verification avoided?
All tests
Yes All participants who underwent the index
test also had the reference standard test
Differential verification avoided?
All tests
Yes Disease status (CAD) diagnosed by coro-
nary angiography.
Incorporation avoided?
All tests
Yes Disease status (CAD) diagnosed by coro-
nary angiography.
Reference standard results blinded?
All tests
Yes Coronary angiography result was reported
by a cardiology team member who was un-
aware of other test results (author corre-
spondence)
Index test results blinded?
All tests
Yes MIBI scan and DSE results were inter-
preted by clinical and technical experts
without knowledge of the other. Both were
conducted before coronary angiography
Relevant clinical information?
All tests
Yes Relevant clinical information was provided
concerning the performance and analysis of
both the index and reference tests (author
correspondence)
Uninterpretable results reported?
All tests
Yes There were no uninterpretable results.
Withdrawals explained?
All tests
Yes There were no withdrawals reported.
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Garg 2000
Clinical features and settings Clinical features
• Patients with DM who were candidates for kidney transplant
Setting
• Sanjay Gandhi Post-Graduate Institute of Medical Sciences, Lucknow, India
Participants • Number: 52
• DM: 100%
• Angina pectoris: not reported
• Hypertension: 100%
• Sex: 88% male
• Age (Mean ± SD): 46 ± 6 years
Study design Cohort study.
Target condition and reference standard(s) Coronary artery stenosis measured by coronary angiography
• Criterion for positive test results was ≥ 50 reduction in cross sectional area. Each
angiogram was independently reviewed by two experienced cardiologists who were
blinded to the clinical data and uninvolved in patient management.
Index and comparator tests DSTS
• Patients received400 mg oral dipyridamole and 1.5 mCi Tl-201 injected IV one
hour after DSTS. Studies were interpreted qualitatively and quantitatively. Planar
thallium was performed in all cases. Normal test results were characterised by: the
patient had no chest pain, no significant ST depression in the ECG during stress, and
no significant perfusion defect. The test was considered positive if significant defects
that were either fixed or reversible were revealed on delayed imaging, based on
circumferential count profile analysis.
Echocardiography
• Resting wall motion abnormality
Resting ECG
• ECGs evaluated for evidence of MI, abnormal ST-T changes, and left ventricular
hypertrophy. Evidence of MI was regarded as positive if significant Q waves were
present in more than one lead. ST-T segment abnormality was noted as present if ST-
segment depression or elevation of at least 1 mm; or inverted T wave in any lead where
the QRS complex had a net positive deflection were detected in the absence of bundle
branch block and left ventricular hypertrophy.
Follow-up Survival data are available.
Notes All patients underwent coronary angiography, echocardiography and resting ECG. 19
patients underwent dipyridamole MPS
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Patients with DM who were candidates for
kidney transplant.
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Garg 2000 (Continued)
Acceptable reference standard?
All tests
Yes Coronary angiography with a reference
standard threshold of ≥ 50% stenosis
Acceptable delay between tests?
All tests
Unclear Likely to be short delay between tests.
Partial verification avoided?
All tests
Yes All participants who underwent an index
test received the reference standard test
Differential verification avoided?
All tests
Yes Disease status (CAD) diagnosed by coro-
nary angiography.
Incorporation avoided?
All tests
Yes Disease status (CAD) diagnosed by coro-
nary angiography.
Reference standard results blinded?
All tests
Yes Each angiogram was independently re-
viewed by two experienced cardiologists
who were blinded to the clinical data and
uninvolved in patient management
Index test results blinded?
All tests
Yes Studies were interpreted qualitatively and
quantitatively.
Relevant clinical information?
All tests
Yes Relevant clinical information was provided
regarding the performance and analysis of
both the index and reference tests
Uninterpretable results reported?
All tests
Yes No results were reported to be uninter-
pretable.
Withdrawals explained?
All tests
Yes All patients missing from the final analysis
were accounted for
Gowdak 2010
Clinical features and settings Clinical features
• Patients with DM on dialysis who were candidates for kidney transplant
Setting
• University of São Paulo Medical School, Brazil
Participants • Number: 219
• DM: 100%
• Angina pectoris: not reported
• Hypertension: 92%
• Sex: 67% male
• Mean age: 57 years
• Mean duration on dialysis: 36 months
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Gowdak 2010 (Continued)
Study design Cross sectional study.
Target condition and reference standard(s) Coronary artery stenosis measured by coronary angiography
• Criterion for positive test results was ≥ 70% reduction in cross sectional area.
Index and comparator tests SPECT+ Sestamibi cardiac scintigraphy
• Pharmacological stress induced by dipyridamole.
Follow-up Data not available.
Notes Data obtained from poster presented at the European Society of Cardiology conference
in 2010 http://spo.escardio.org/AbstractDetails.aspx?id=91377
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Patients with DM who were candidates for
kidney transplant.
Acceptable reference standard?
All tests
Yes Coronary angiography with a reference
standard threshold of ≥ 70% stenosis
Acceptable delay between tests?
All tests
Unclear Not reported.
Partial verification avoided?
All tests
Yes All patients underwent coronary angiogra-
phy.
Differential verification avoided?
All tests
Yes Disease status (CAD) diagnosed by coro-
nary angiography.
Incorporation avoided?
All tests
Yes Disease status (CAD) diagnosed by coro-
nary angiography.
Reference standard results blinded?
All tests
Unclear Not reported.
Index test results blinded?
All tests
Unclear Not reported.
Relevant clinical information?
All tests
Yes Relevant clinical information was provided
regarding the performance and analysis of
both the index and reference tests
Uninterpretable results reported?
All tests
Yes No uninterpretable results present.
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Gowdak 2010 (Continued)
Withdrawals explained?
All tests
Yes No withdrawals reported.
Herzog 1999
Clinical features and settings Clinical features
Patients referred for kidney transplantation evaluation from June 1992 to January 1995
• ESKD from diabetic kidney disease or other causes
• unable to perform treadmill exercise
• ≥ 2 CAD risk factors: male; HTN; hypercholesterolaemia (total cholesterol level
240 mg/dL or low-density lipoprotein cholesterol level 160 mg/dL); history of
smoking; family history or any evidence suggestive of IHD (angina, effort dyspnoea,
previous MI by history or ECG, or abnormal global or regional left ventricular
function)
Setting
• Hennepin County Medical Center, Minneapolis, Minnesota, USA
Participants • Patients were predominantly middle-aged white men. Nearly all patients (92%)
were undergoing chronic haemodialysis
• Number: 50
• DM: 82%
• Angina pectoris: 16%
• Hypertension: 94%
• Sex: 60% male
Exclusion criteria
• Significant aortic stenosis; unstable angina; inability to obtain informed consent;
previous coronary angiography
Study design Cohort study
Target condition and reference standard(s) Coronary artery stenosis measured by coronary angiography
• Criterion for positive test result was ≥ 70% reduction in cross sectional area by
quantitative coronary angiography.
Index and comparator tests DSE
• End points for stopping drug infusion were: new inducible wall motion
abnormalities involving ≥ 2 coronary artery vascular territories, intolerable patient
discomfort, angina with ≥ 2 mm ST segment depression or elevation in a previously
normal ECG lead, significant tachyarrhythmia (sustained supraventricular tachycardia
or ≥ 3-beat run of ventricular tachycardia), symptomatic severe hypotension, SBP ≥
240 mm Hg or DBP ≥ 120 mm Hg, attaining target heart rate ([220 - age] × 0.85), or
reaching the maximum dose of dobutamine and atropine.
• DSE studies were analysed in digital format independently by three
echocardiographers blinded to angiographic data. DSE study was defined as positive
for inducible ischaemia when ≥ 1 normal segments developed absolute or relative
hypokinesis with stress compared with other segments or an abnormal segment at rest
had deterioration of regional systolic thickening with stress. DSE study result was
normal if all segments were hyperdynamic with stress. If a resting baseline regional wall
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Herzog 1999 (Continued)
motion abnormality was unchanged with stress and all other segments became
hyperdynamic, the DSE result was classified as a baseline regional wall motion
abnormality with no inducible ischaemia.
Follow-up Patients were followed up for a mean of 22.5 ± 10.1 months.
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Patients referred for kidney transplantation
evaluation.
Acceptable reference standard?
All tests
Yes Coronary angiography with a reference
standard threshold of ≥ 70% stenosis
Acceptable delay between tests?
All tests
Yes 47 patients had angiography within 2
weeks after DSE (median, 2 days; mean,
12.4 ± 41 days); three patients had angio-
graphic studies at 69, 85, and 280 days af-
ter DSE (angiography was delayed wound
infection (1 patient) and psychosocial rea-
sons (2 patients)
Partial verification avoided?
All tests
Yes All participants who underwent the index
test received the reference standard test
Differential verification avoided?
All tests
Yes Disease status (CAD) diagnosed by coro-
nary angiography.
Incorporation avoided?
All tests
Yes Disease status (CAD) diagnosed by coro-
nary angiography.
Reference standard results blinded?
All tests
Yes All lesions occurring in the major coronary
artery segments or their proximal branches
were visually identified, and an initial qual-
itative assessment made by a skilled reader
blinded to all clinical data
Index test results blinded?
All tests
Yes All DSE studies were analysed in digital for-
mat independently by three echocardiogra-
phers blinded to angiographic data
Relevant clinical information?
All tests
Yes Relevant clinical information was provided
regarding the performance and analysis of
both the index and reference tests
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Uninterpretable results reported?
All tests
Yes No uninterpretable results were present.
Withdrawals explained?
All tests
Yes 55 eligible patients participated; 2 were ex-
cluded for unstable angina before sched-
uled testing; 3 underwent DSE and sub-
sequently declined coronary angiography;
50 patients completed the research proto-
col. 39/50 patients qualified for DSE by the
prespecified inclusion criterion of ESKD
secondary to diabetic nephropathy (regard-
less of exercise capacity). The remaining 11
patients were unable to perform treadmill
exercise because of peripheral vascular dis-
ease (4 patients), musculoskeletal disease (4
patients), lung disease (1 patient), and gen-
eralised fatigue (2 patients)
Jassal 2007
Clinical features and settings Clinical features
• Between 2004 and 2006, 30 patients were prospectively evaluated who
underwent both DSE and coronary angiography. This population included 12 patients
(5 male, mean age 59 ± 13 years) referred to rule out CAD with normal kidney
function (Cr < 2.0 mg/dL) and 18 patients (8 male, mean age 55 ± 12 years) with
CKD (Cr > 2.0 mg/dL) on haemodialysis referred for pre-renal transplant workup.
Setting
• Boniface General Hospital, Manitoba, Canada
Participants • Number: 18
• DM: 38%
• Angina pectoris: percentage not reported
• Hypertension: 77%
• Sex: 44% male
Study design Cross sectional study
Target condition and reference standard(s) Coronary artery stenosis measured by coronary angiography
• Criterion for positive test results was ≥ 50% reduction in cross sectional area.
Index and comparator tests DSE
• Beta-adrenergic blocking agents were withdrawn for 24 hours before the study.
• Dobutamine was infused at doses of 5, 10, 20, 30, and 40 mg/kg/min for 3
minutes each. Images were analysed using the standard16-segment model
Follow-up None reported
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Jassal 2007 (Continued)
Notes Only data for the 18 patients referred for pre-renal transplant workup were considered.
Sufficient data in published report to create 2 x 2 table
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Patients who presented for cardiac evalua-
tion before kidney transplantation
Acceptable reference standard?
All tests
Yes Coronary angiography with a reference
standard threshold of ≥ 50% stenosis
Acceptable delay between tests?
All tests
Unclear Likely to be short delay between tests.
Partial verification avoided?
All tests
Yes All participants who underwent the index
test also had the reference standard test
Differential verification avoided?
All tests
Yes Disease status (CAD) diagnosed by coro-
nary angiography.
Incorporation avoided?
All tests
Yes Disease status (CAD) diagnosed by coro-
nary angiography.
Reference standard results blinded?
All tests
Unclear Not reported.
Index test results blinded?
All tests
Unclear Not reported.
Relevant clinical information?
All tests
Yes Relevant clinical information was provided
regarding the performance and analysis of
both the index and reference tests
Uninterpretable results reported?
All tests
Yes No uninterpretable results were present.
Withdrawals explained?
All tests
Yes No withdrawals were reported.
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Krawczynska 1988
Clinical features and settings Clinical features
• 305 patients with ESKD undergoing cardiac assessment prior to kidney transplant
Setting
• Emory University School of Medicine, Georgia, USA
Participants • Number: 46
• DM: percentage not reported
• Angina pectoris: percentage not reported
• Hypertension: percentage not reported
• Sex: not reported
Study design Cohort study
Target condition and reference standard(s) Coronary artery stenosis measured by coronary angiography
• Criterion for positive test results was ≥ 50% reduction in cross-sectional area.
Index and comparator tests Thalium-201 Cardiac SPECT
• Stress was induced in 200 patients via exercise, 105 with dipyridamole. Reversible
perfusion deficits constituted a positive test.
Follow-up Postoperative data available for outcomes of death and adverse cardiac events
Notes Only available in abstract form (presentation).
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Prerenal transplant cardiac assessment. 305
ESKD patients waiting kidney transplan-
tation
Acceptable reference standard?
All tests
Yes Coronary angiography with a reference
standard threshold ≥ 50% stenosis
Acceptable delay between tests?
All tests
Unclear Likely to be short delay between tests.
Partial verification avoided?
All tests
No 38 patients received both coronary angiog-
raphy and stress test
Differential verification avoided?
All tests
Yes Disease status (CAD) diagnosed by coro-
nary angiography.
Incorporation avoided?
All tests
Yes Disease status (CAD) diagnosed by coro-
nary angiography.
Reference standard results blinded?
All tests
Unclear Not stated in abstract.
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Krawczynska 1988 (Continued)
Index test results blinded?
All tests
Unclear Not stated in abstract.
Relevant clinical information?
All tests
Unclear Insufficient clinical information provided
about performance and analysis of the in-
dex and reference tests
Uninterpretable results reported?
All tests
Yes No results were reported to be uninter-
pretable.
Withdrawals explained?
All tests
Yes All patients missing from the final analysis
were accounted for
Marwick 1989
Clinical features and settings Clinical features
• ESKD patients undergoing coronary angiography as part of transplant workup
over a 2 year period. Patients were selected on the basis of longstanding diabetes history
of chest pain or previous MI, or age > 40.
Setting
• Cleveland Clinic, Ohio, USA
Participants • Number: 86
• DM: 29%
• Angina pectoris or IHD: 11%
• Hypertension: 36%
• Sex: 27% male
Study design Cross sectional study.
Target condition and reference standard(s) Coronary artery stenosis measured by coronary angiography
• CAD was defined as the presence of ≥ 1 coronary arteries with ≥ 50% diameter
stenosis
Index and comparator tests DSF
• Results were classified based on the presence or absence of calcification of the
coronary arteries
Follow-up None reported.
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes ESKD patients undergoing cardiac evalua-
tion as part of transplant workup
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Marwick 1989 (Continued)
Acceptable reference standard?
All tests
Yes Coronary angiography with a reference
standard threshold of ≥ 50% stenosis
Acceptable delay between tests?
All tests
Yes Tests performed at the same time.
Partial verification avoided?
All tests
Yes All participants who underwent an index
test received the reference standard test
Differential verification avoided?
All tests
Yes Disease status (CAD) diagnosed by coro-
nary angiography.
Incorporation avoided?
All tests
Yes Disease status (CAD) diagnosed by coro-
nary angiography.
Reference standard results blinded?
All tests
Yes Author correspondence.
Index test results blinded?
All tests
Yes Author correspondence.
Relevant clinical information?
All tests
Yes Relevant clinical information provided re-
garding performance and analysis of the in-
dex and reference tests
Uninterpretable results reported?
All tests
Yes No results were reported to be uninter-
pretable.
Withdrawals explained?
All tests
Yes No withdrawals were reported.
Marwick 1990
Clinical features and settings Clinical features
• ESKD patients undergoing coronary angiography as part of transplant workup
with longstanding diabetes, history of chest pain or previous MI, or age > 40
Setting
• Cleveland Clinic, Ohio, USA
Participants • Number: 45
• DM: 51%
• Angina pectoris or IHD: 33%
• Hypertension: 81%
• Sex: 71% male
Exclusion criteria
• Recent angina or MI
Study design Cohort study
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Marwick 1990 (Continued)
Target condition and reference standard(s) Coronary artery stenosis measured by coronary angiography
• Each angiogram was independently assessed by a reviewer blinded to
fluorographic results.
• CAD was defined as presence of ≥ 1 coronary arteries with ≥ 70% diameter
stenosis.
Index and comparator tests Dipyridamole SPECT Thallium Imaging
• Images were displayed using a semi-quantitative system with a segmented colour
scale. Scans were interpreted by an experienced observer without knowledge of
catheterisation results, and were classified into groups with normal perfusion, fixed
defect or reversible defect.
Follow-up Follow up over 25 ± 14 months.
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes ESKD patients undergoing cardiac evalua-
tion as part of transplant workup
Acceptable reference standard?
All tests
Yes Coronary angiography with a reference
standard threshold of ≥ 70% stenosis
Acceptable delay between tests?
All tests
Yes Thallium scanning was performed within
a week of coronary angiography
Partial verification avoided?
All tests
Yes All participants who received an index test
received the reference standard test
Differential verification avoided?
All tests
Yes Disease status (CAD) diagnosed by coro-
nary angiography.
Incorporation avoided?
All tests
Yes Disease status (CAD) diagnosed by coro-
nary angiography.
Reference standard results blinded?
All tests
Yes Author correspondence.
Index test results blinded?
All tests
Yes Author correspondence.
Relevant clinical information?
All tests
Yes Relevant clinical information was provided
regarding performance and analysis of the
index and reference tests
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Marwick 1990 (Continued)
Uninterpretable results reported?
All tests
Yes No results were reported to be uninter-
pretable.
Withdrawals explained?
All tests
Yes No withdrawals were reported.
Modi 2006
Clinical features and settings Clinical features
• ESKD patients with hypertension on maintenance dialysis undergoing pre-
transplant coronary angiography as per the institutional protocol if they were aged > 40
years to rule out CAD as part of transplant workup
Setting
• Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India
Participants • Number: 105
• DM: 61/105 (58%)
• Hypertension: all were hypertensive
• Sex: 102 (97.1%) male
• Age (mean ± SD): 51.6 ± 6.2 years (range 38 to 64 years)
Study design Cross sectional study.
Target condition and reference standard(s) Coronary artery stenosis measured by coronary angiography
• CAD defined as presence of ≥ 1 coronary arteries with ≥ 50% diameter stenosis
Index and comparator tests CIMT measurement
• CIMT measurement was conducted on USG B mode 7.5 MHZ probe. At least
three readings were taken, and the average of three readings was taken for evaluation.
IMT on both sides was calculated and averaged. Plaques were defined as focal widening
relative to the adjacent segments, with protrusion into the lumen, composed either of
only calcified deposits or a combination of calcification and non-calcified material. The
site and extent of lesions were not quantified.
• Patients were further divided into two groups according to average CIMT
(average IMT > 0.75 mm and those with IMT < 0.75 mm).
Follow-up None reported.
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes ESKD patients undergoing cardiac evalua-
tion as part of transplant workup
64Cardiac testing for coronary artery disease in potential kidney transplant recipients (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Modi 2006 (Continued)
Acceptable reference standard?
All tests
Yes Yes, coronary angiography with a reference
standard threshold of ≥ 50% stenosis
Acceptable delay between tests?
All tests
Unclear Unclear, but likely to be only short delay
between tests.
Partial verification avoided?
All tests
Yes All participants who received an index test
received the reference standard test
Differential verification avoided?
All tests
Yes This was not an issue in this study. Disease
status (CAD) is diagnosed only through
coronary angiography
Incorporation avoided?
All tests
Yes This was not an issue in this study. Disease
status (CAD) is diagnosed only through
coronary angiography
Reference standard results blinded?
All tests
Yes Reference standard performed before index
test. Therefore it was not influenced by re-
sults of index test
Index test results blinded?
All tests
Yes An operator, who was blinded with respect
to the results of the coronary angiography,
measured CIMT in all patients prior to
coronary angiography and recorded it on
videotape. Two independent observers who
were blinded to the result of coronary an-
giography, measured CIMT offline to vali-
date its predictive accuracy as a noninvasive
test in predicting the presence or absence
of CAD
Relevant clinical information?
All tests
Yes Relevant clinical information was provided
regarding the performance and analysis of
both the index and reference tests
Uninterpretable results reported?
All tests
Yes No results were reported to be uninter-
pretable.
Withdrawals explained?
All tests
Yes No withdrawals were present.
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Reis 1995
Clinical features and settings Clinical features
• ESKD patients on dialysis undergoing cardiac evaluation (DSE) as part of
transplant workup. Antihypertensive treatment and aggressive DM control were
undertaken as clinically indicated
Setting
• University of Michigan, Ann Arbor, Michigan, USA
Participants • Number: 97 patients underwent screening; only 30 patients received both DSE
and coronary angiography
• DM: 64%
• Angina pectoris or history of IHD: 30%
• Hypertension: 96%
• Sex: 63% male
Study design Cohort study.
Target condition and reference standard(s) Coronary artery stenosis measured by coronary angiography
• CAD was defined as presence of ≥ 1 coronary arteries with ≥ 50% stenosis.
Index and comparator tests DSE
• After completing a resting echocardiogram, stepwise infusion of dobutamine
starting at 10 pg/kg/min, and increasing to 20 and a peak of 30 or 40 pg/kg/min in 3-
minute stages was initiated.
• All DSE studies were reviewed by experienced echocardiographers blinded to
angiographic data and classified as:
◦ normal response: global increase in contractility, with an associated increase
in ejection fraction, implying an absence of significant obstructive CAD (no regional
wall motion abnormalities were seen at rest or during DSE).
◦ inducible ischaemia: wall motion abnormalities during DSE in 22 segments
in regions that were normal at baseline, implying CAD without prior MI.
◦ fixed response: wall motion abnormality at baseline and no change during
DSE implying prior MI without inducible ischaemia.
◦ mixed response: new and/or worsening wall motion abnormality in a patient
with a wall motion abnormality at rest, implying prior MI with additional inducible
ischaemia.
Follow-up 12 ± 6 months.
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes ESKD patients undergoing cardiac evalua-
tion as part of transplant workup
Acceptable reference standard?
All tests
Yes Coronary angiography with a reference
standard threshold of ≥ 50% stenosis
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Reis 1995 (Continued)
Acceptable delay between tests?
All tests
Yes Within 4 months.
Partial verification avoided?
All tests
No Coronary angiography was performed in
30/97 patients.
Differential verification avoided?
All tests
Yes Disease status (CAD) diagnosed by coro-
nary angiography.
Incorporation avoided?
All tests
Yes Disease status (CAD) diagnosed by coro-
nary angiography.
Reference standard results blinded?
All tests
Unclear Not reported.
Index test results blinded?
All tests
Yes All DSE studies were reviewed by experi-
enced echocardiographers blinded to an-
giographic data
Relevant clinical information?
All tests
Yes Relevant clinical information was provided
regarding the performance and analysis of
both the index and reference tests
Uninterpretable results reported?
All tests
Yes No results were reported to be uninter-
pretable.
Withdrawals explained?
All tests
Yes All patients missing from the final analysis
were accounted for
Rosario 2010
Clinical features and settings Clinical features
• CKD patients in haemodialysis programs referred for kidney coronary
angiography as part of a kidney transplant evaluation. The clinical indication for
coronary angiography was based on the fact that the patients belonged to the group
under high risk for CAD either due to symptoms and/or previous invasive exams that
would lead to a suspicion of CVD.
Setting
• Instituto do Coração (InCor) do Hospital das Clínicas da Faculdade de Medicina
da Universidade de São Paulo, São Paulo, Brazil.
Participants • Number: 97
• DM: 38%
• Angina pectoris or IHD: 29%
• Hypertension: 90%
• Sex: 65% male
Study design Cohort study.
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Rosario 2010 (Continued)
Target condition and reference standard(s) Coronary artery stenosis measured by coronary angiography
• CAD defined as presence of ≥ 1 coronary arteries with ≥ 70% diameter stenosis.
Index and comparator tests Multi-detector CT exams
• Performed in 16 and 64-column detector-row. Patients’ heart rates during
examination = 61.1 ± 6.9 bpm. Patients with rates > 70 bpm on arrival for CT scan
received IV beta-blocker (metoprolol)to achieve 60 bpm, or the maximum dose (15
mg), since the protocol included associated coronary angiotomography acquisition.
Calcium score obtained through prospective acquisition, and synchronised to ECG
tracing. Images acquired were 3.0 mm thick, and view field was from 200 to 220 mm
for chest axial images covering all cardiac area and allowing visualisation of coronary
arteries and possible calcification on coronary artery topography. Images were acquired
at a diastolic moment that was defined following patient’s heart rate.
Follow-up Follow-up ongoing.
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes CKD patients already in a haemodialysis
program and referred to be submitted to
kidney transplant
Acceptable reference standard?
All tests
Yes Yes, coronary angiography with a reference
standard threshold of ≥ 50 and 70% steno-
sis
Acceptable delay between tests?
All tests
Yes Time elapsed between Multi-detector CT
and coronary angiography was on average
99.03 days, SD 87.65 days, and median 79
days. Minimum interval was 2 days, and
maximum interval was 380 days. Only 2
cases exceeded 1 year, and 16 cases had an
interval over 6 months
Partial verification avoided?
All tests
Yes All participants who received an index test
received the reference standard test
Differential verification avoided?
All tests
Yes This was not an issue in this study. Disease
status (CAD) is diagnosed only through
coronary angiography
Incorporation avoided?
All tests
Yes This was not an issue in this study. Disease
status (CAD) is diagnosed only through
coronary angiography
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Rosario 2010 (Continued)
Reference standard results blinded?
All tests
Yes An observer experienced in QCA tech-
nique and who did not participate in the
Multi-detector CT analysis - also blind and
independent
Index test results blinded?
All tests
Unclear Not reported.
Relevant clinical information?
All tests
Yes Relevant clinical information was provided
regarding the performance and analysis of
both the index and reference tests
Uninterpretable results reported?
All tests
Yes No results were reported to be uninter-
pretable.
Withdrawals explained?
All tests
Yes No withdrawals were present.
Sharma 2005
Clinical features and settings Clinical features
• ESKD patients undergoing cardiac evaluation as part of transplant workup
Setting
• St George’s Hospital, London, UK
Participants • Number: 128
• Dialysis: 54%
• Principal cause of ESKD: DM (39 patients)
• DM: 39%
• Angina pectoris or IHD: 42%
• Hypertension: 91%
• Sex: 64% male
Exclusion criteria
• Age < 18 years; severe aortic stenosis; unstable angina; inability to consent.
Study design Cohort study
Target condition and reference standard(s) Coronary artery stenosis measured by coronary angiography
• CAD defined as the presence of ≥ 1 coronary arteries with ≥ 70% diameter
stenosis.
Index and comparator tests • Exercise ECG
◦ Patients had treadmill exercise testing according to standard Bruce protocol
to limiting symptoms. The 12 lead ECG was recorded continuously and the following
documented: exercise time to limiting symptom, maximal ST segment change, Duke
multivariate prognostic score, maximal heart rate, maximal systolic blood pressure,
limiting symptoms. The test was stopped if: limiting symptoms (angina, shortness of
breath, dizziness, lethargy), ST depression > 3 mm, ventricular tachycardia, drop in
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Sharma 2005 (Continued)
blood pressure > 30 mm Hg, SBP rise > 230 mm Hg occurred. Patients were given an
angina score: 0 = none, 1 = non-limiting angina, 2 = limiting angina. Duke score was
calculated as: total treadmill time (min)-5 X magnitude of maximal ST depression
(mm)- 4 X angina index. Horizontal or down sloping ST depression > 1mm measured
80 ms after the J point, and ST elevation > 1 mm measured 40 ms after the J point,
were regarded as positive results. The test was described as inconclusive if stopped
before 85% predicted heart rate could be achieved with no cardiac symptoms or
significant changes at that stage.
• DSE
◦ An abnormal response was described as the occurrence under stress of
hypokinesia, akinesia or dyskinesia in one or more resting normal segments and/or
worsening of wall motion in one or more resting hypokinetic segments.
• Echocardiography
• Mitral annular calcification
◦ The presence of mitral annular calcification was defined as an echo dense
band visualised throughout systole and diastole, distinguishable from the posterior
mitral valve leaflet, and located anterior and parallel to the posterior left ventricular
wall on M-mode recordings.
• Resting wall motion abnormality
• Resting ECG
◦ The ECG was considered abnormal if any of the following criteria were met
in any of the standard limb leads or precordial leads, except AVR or V1: pathological Q
waves, left ventricular hypertrophy by Sokolow-Lyon criteria or Cornell index, ST
depression ≥ 1 mm, ST elevation ≥ 1 mm, T wave inversion or bundle branch block
(QRS ≥120 ms).
Follow-up Patients were followed up for 1.32 ± 0.48 years (range 0.19 ± 2.12 years)
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes ESKD patients undergoing cardiac evalua-
tion as part of transplant workup
Acceptable reference standard?
All tests
Yes Coronary angiography with a reference
standard threshold of ≥ 70% stenosis
Acceptable delay between tests?
All tests
Unclear Likely to be short delay between tests.
Partial verification avoided?
All tests
Yes All participants who underwent the index
test received the reference standard test
Differential verification avoided?
All tests
Yes Disease status (CAD) diagnosed by coro-
nary angiography.
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Sharma 2005 (Continued)
Incorporation avoided?
All tests
Yes Disease status (CAD) diagnosed by coro-
nary angiography.
Reference standard results blinded?
All tests
Yes Angiograms were interpreted by two expe-
rienced, blinded observers with consensus
for disagreement
Index test results blinded?
All tests
Yes All images were reported offline by two ex-
perienced observers blinded to the rest of
the study
Relevant clinical information?
All tests
Yes Relevant clinical information was provided
regarding performance and analysis of both
the index and reference tests
Uninterpretable results reported?
All tests
Yes No results were reported to be uninter-
pretable.
Withdrawals explained?
All tests
Yes No withdrawals were reported.
Sharma 2009
Clinical features and settings Clinical features
• ESKD patients undergoing cardiac evaluation as part of transplant workup
Setting
• Ealing Hospital NHS Trust, Middlesex, UK
Participants • Number: 143
• DM: 38%
• Angina pectoris or IHD: 27%
• Hypertension: 92%
• Sex: 64% male
Exclusion criteria
• < 18 years; severe aortic stenosis; unstable angina
Study design Cohort study
Target condition and reference standard(s) Coronary artery stenosis measured by coronary angiography
• CAD defined as presence of ≥ 1 coronary arteries with ≥ 70% diameter stenosis
Index and comparator tests DSE
• Peak systolic velocity measured by tissue Doppler imaging: The percentage of
ischaemic myocardium was calculated from tissue Doppler imaging analysis as the
number of ischaemic segments divided by the number of visualised segments.
• Conventional visual assessment: Semi-quantitative analysis was performed using a
17-segment model. An abnormal response was described by the occurrence under stress
of a new or worsening wall motion abnormality in ≥ 1 left ventricular segment. The
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Sharma 2009 (Continued)
severity of ischaemia was determined by the number of ischaemic segments seen during
dobutamine stress and by the peak wall motion score index.
Echocardiography
• Resting wall motion abnormality
Follow-up Mean follow-up was 2.3 ± 0.7 years (range 0.2 to 3.3 years)
Notes The authors reported that this study population was different from the study results
published in 2005. We were able to create 2 x 2 tables using tabulated results from the
study
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes ESKD patients undergoing cardiac evalua-
tion as part of transplant workup
Acceptable reference standard?
All tests
Yes Coronary angiography with a reference
standard threshold of ≥ 70% stenosis
Acceptable delay between tests?
All tests
Unclear Unclear, but likely to be only short delay
between tests.
Partial verification avoided?
All tests
Yes All participants who underwent the index
test received the reference standard test
Differential verification avoided?
All tests
Yes This was not an issue in this study. Disease
status (CAD) is diagnosed only through
coronary angiography
Incorporation avoided?
All tests
Yes This was not an issue in this study. Disease
status (CAD) is diagnosed only through
coronary angiography
Reference standard results blinded?
All tests
Yes Angiograms were interpreted blindly by
two experienced observers and consensus
was obtained in discordant cases from a
third experienced operator
Index test results blinded?
All tests
Yes The analysis of conventional and tissue
Doppler imaging stress echo data was per-
formed off-line by two independent, expe-
rienced observers blinded to clinical and
coronary angiography data. Consensus was
obtained in discordant cases from a third
experienced operator
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Sharma 2009 (Continued)
Relevant clinical information?
All tests
Yes All patients missing from the final analysis
were accounted for
Uninterpretable results reported?
All tests
Yes No results were reported to be uninter-
pretable.
Withdrawals explained?
All tests
Yes No withdrawals were reported.
Sharples 2004
Clinical features and settings Clinical features
• ESKD patients referred for coronary angiography as part of cardiac work up
before kidney transplantation
Setting
• Two inner city renal units in Royal London and St Bartholomew’s Hospital,
London, UK
Participants • Number: 18
• DM: percentage not reported
• Angina pectoris: percentage not reported
• Hypertension: percentage not reported
• Sex: 50% male
• Man age: 53.9 years (range 31 to 73 years)
• Mean time on RRT: 27.4 months (range 4 to 111 months)
Study design Cross sectional study
Target condition and reference standard(s) Coronary artery stenosis measured by coronary angiography
• CAD defined as presence of ≥ 1 coronary arteries with at least 50% stenosis.
Index and comparator tests EBCT
• Images were performed with a 100-ms scanning time and a single slice thickness
of 3 mm. 36 to 40 tomographic slices were obtained for each subject during 2 breath-
holding sessions. The degree of coronary artery calcification was calculated by
multiplying the area of each calcified lesion by a weighting factor corresponding to the
peak pixel intensity for each lesion to yield a lesion-specific calcification score. The
proximal segments of the left main stem, left anterior descending, left circumflex and
right coronary arteries were examined.
Follow-up None reported.
Notes Results reported per vessel, not per patient. Insufficient data to construct meaningful 2
x 2 table. Therefore, study did not contribute data to the meta-analysis
Table of Methodological Quality Table of Methodological
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Item Authors’ judgement Description
Representative spectrum?
All tests
Yes ESKD patients assessed for CAD before
kidney transplant.
Acceptable reference standard?
All tests
Yes Coronary angiography with a reference
standard threshold of ≥ 75% stenosis
Acceptable delay between tests?
All tests
Unclear Likely to be short delay between tests.
Partial verification avoided?
All tests
Yes All participants who underwent the index
test received the reference standard test
Differential verification avoided?
All tests
Yes Disease status (CAD) diagnosed by coro-
nary angiography.
Incorporation avoided?
All tests
Yes Disease status (CAD) diagnosed by coro-
nary angiography.
Reference standard results blinded?
All tests
Yes Analysis of the coronary angiograms was
performed using a digital analysis system
operated by a cardiologist blinded to the
calcification score
Index test results blinded?
All tests
Yes The acquired images were scored with the
use of Imatron software by a single radiolo-
gist blinded to the clinical or angiographic
history of the patient
Relevant clinical information?
All tests
Yes Relevant clinical information was provided
regarding the performance and analysis of
both the index and reference tests
Uninterpretable results reported?
All tests
Yes There were no uninterpretable results.
Withdrawals explained?
All tests
Yes There were no withdrawals.
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Vandenberg 1996
Clinical features and settings Clinical features
• Patients with kidney disease and DM referred for kidney and/or pancreas
transplantation from 1988 to 1993 undergoing cardiac evaluation as part of transplant
workup with no history of angina, MI, coronary artery bypass surgery, or percutaneous
transluminal coronary angioplasty; pharmacologic stress thallium scintigraphy and/or
exercise radionuclide ventriculography performed as part of the evaluation; and
coronary artery angiography performed within 6 months after the radionuclide
evaluation (and no cardiac symptoms in the interim period).
Setting
• Cardiovascular Center, University of Iowa College of Medicine, Iowa, USA
Participants • Number: 47
• DM: 100%
• Angina pectoris or IHD: Nil
• Hypertension: 74%. 35/74 (74%)
◦ Patients were taking antihypertensive medications, including beta blockers
and calcium channel blockers; medications were continued during stress testing
• Sex: not reported
Study design Cohort study
Target condition and reference standard(s) Coronary artery stenosis measured by coronary angiography
• CAD defined as presence of ≥ 1 coronary arteries with ≥ 75% diameter stenosis.
Separate data available for 50% stenosis
Index and comparator tests Pharmacologic stress thallium scintigraphy
• IV dipyridamole was infused at a rate of 0.142 mg/kg per min for 4 min. IV
adenosine was infused at a rate of 0.14 mg/kg per min for 6 min. Thallium-201 (3
mCi) was injected IV 5 min after the completion of the dipyridamole infusion or 4
min after the beginning of the adenosine infusion. Imaging was performed within 10
min with a gamma-camera. Planar images in anterior and lateral projections were
obtained and were followed immediately by single-photon emission CT imaging.
Images were interpreted by consensus of two experienced radiologists who were
unaware of the angiography results. Test results were considered abnormal if either a
fixed or a reversible defect was present.
Exercise radionuclide ventriculography
• Radionuclide ventriculography was performed in 40 patients using a modified in
vivo red blood cell-labelling technique with an initial IV injection of 5.1 mg of
stannous pyrophosphate, followed by 25 to 30 mCi of technetium-99m pertechnetate.
Patients performed semi supine exercise with a bicycle ergometer table during
continuous 12-lead ECG monitoring. Exercise was begun at a pedal speed of 50 rpm
and a work load of about 50 watts, which was increased by 10 watts every 30 sec to a
symptom-limited maximum. Heart rate and blood pressure were recorded at each
exercise level. Images were obtained in the left anterior oblique projection at peak
exercise and ejection fraction was calculated from this image. Exercise was considered
adequate if the peak rate pressure product was > 20,000 or if the rate pressure product
at least doubled from baseline to peak exercise.
• A test result was considered abnormal if any of the following were present:
◦ resting ejection fraction of < 50%
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Vandenberg 1996 (Continued)
◦ failure to increase ejection fraction by at least 5 percentage points (in female
subjects and in those with a resting ejection fraction of > 60%, the failure to increase
ejection fraction was not considered abnormal); or
◦ a new wall motion abnormality with exercise
Follow-up The mean time from thallium scintigraphy to the latest follow-up visit was 35 ± 19
months
Notes
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Renal failure patients undergoing cardiac
evaluation as part of transplant workup
Acceptable reference standard?
All tests
Yes Yes, coronary angiography with a reference
standard threshold of ≥75% stenosis
Acceptable delay between tests?
All tests
Yes Angiography was performed 55 ± 42 days
after thallium scintigraphy in 42 patients
and 50 ± 45 days after exercise radionuclide
ventriculography in 40 patients
Partial verification avoided?
All tests
Yes All participants who received an index test
received the reference standard test
Differential verification avoided?
All tests
Yes This was not an issue in this study. Disease
status (CAD) is diagnosed only through
coronary angiography
Incorporation avoided?
All tests
Yes This was not an issue in this study. Disease
status (CAD) is diagnosed only through
coronary angiography
Reference standard results blinded?
All tests
Yes Measurements were made by a single ob-
server without knowledge of the results of
the imaging tests
Index test results blinded?
All tests
Yes Images were interpreted by the consensus
of two experienced radiologists who were
unaware of the angiography results
Relevant clinical information?
All tests
Yes Relevant clinical information was provided
regarding the performance and analysis of
both the index and reference tests
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Vandenberg 1996 (Continued)
Uninterpretable results reported?
All tests
Yes Yes. One MPS was technically suboptimal
and was therefore not included in the anal-
ysis. Exercise ventriculography was subop-
timal in five patients and they were not in-
cluded in the analysis
Withdrawals explained?
All tests
Yes All patients missing from the final analysis
were accounted for
West 2000
Clinical features and settings Clinical features
• Dialysis-dependent renal transplant candidates evaluated between 1 January l993
and 1 March l995 were screened for cardiac high-risk factors (identified as those with
diabetes mellitus, previous MI, age 50 years or more cerebral and/or peripheral vascular
disease, CHF, class I or II angina (Canadian Cardiovascular Society classification), and
dialysis dependency of more than 5 years).
Setting
• Geisinger Medical Center, Danville, Pennsylvannia, USA
Participants • Number: 33
• DM: percentage not reported
• Angina pectoris or IHD: percentage not reported
• Hypertension: percentage not reported
• Sex: not reported
Study design Cohort study
Target condition and reference standard(s) Coronary artery stenosis measured by coronary angiography
• CAD was defined as the presence of one or more coronary arteries with 70% or
greater diameter stenosis, or greater than 50% in left main coronary artery.
Index and comparator tests DSE
• DSE was performed the day after dialysis to avoid hypertensive blood pressure
response from volume overload. A standardised DSE protocol was used. DSE findings
were graded as negative if normal wall motion was present and positive when:
◦ CAD: fixed, inducible, or mixed segmental wall motion abnormalities
◦ Cardiomyopathy: diffuse wall motion abnormalities or
◦ Primary valvular heart disease: severe aortic stenosis, aortic insufficiency,
mitral stenosis, or mitral regurgitation secondary to primary leaflet abnormalities were
present
Follow-up Patients were followed up for an unspecified time.
Notes
Table of Methodological Quality Table of Methodological
77Cardiac testing for coronary artery disease in potential kidney transplant recipients (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
West 2000 (Continued)
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes ESKD patients undergoing cardiac evalua-
tion as part of transplant workup
Acceptable reference standard?
All tests
Yes Coronary artery stenosis measured by coro-
nary angiography. CAD defined as the pres-
ence of ≥ 1 coronary arteries with ≥ 70%
diameter stenosis, or > 50% in left main
coronary artery
Acceptable delay between tests?
All tests
Unclear Likely to be only delay between tests.
Partial verification avoided?
All tests
Yes All participants who underwent the index
test received the reference standard test
Differential verification avoided?
All tests
Yes Disease status (CAD) diagnosed by coro-
nary angiography.
Incorporation avoided?
All tests
Yes Disease status (CAD) diagnosed by coro-
nary angiography.
Reference standard results blinded?
All tests
Unclear Not reported.
Index test results blinded?
All tests
Unclear Not reported.
Relevant clinical information?
All tests
Yes Relevant clinical information was provided
regarding the performance and analysis of
the index and reference tests
Uninterpretable results reported?
All tests
Yes There were no uninterpretable results.
Withdrawals explained?
All tests
Yes Nine patients were excluded because of
prior coronary angiography (5), class III ±
IV angina (3), and refusal to participate in
the study (1)
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Worthley 2003
Clinical features and settings Clinical features
• ESKD patients with multiple risk factors (> 60 years; HTN; DM; history of
smoking; family history of CAD; hypercholesterolaemia) undergoing cardiac
evaluation as part of transplant workup
Setting
• North Western Adelaide Health Service, University of Adelaide, Australia
Participants • Number: 40
• DM: 78%
• Angina pectoris or IHD: 18%
• Hypertension: 98%
• Sex: 48% male
Exclusion criteria
• Normal coronary angiography within the preceding 2 years; coronary
revascularisation within the last 12 months; evidence of previous Q-wave infarction on
ECG at rest; class III to IV angina pectoris at study entry
Study design Cohort study
Target condition and reference standard(s) Coronary artery stenosis measured by coronary angiography
• Angiograms were assessed by 2 cardiologists who were blinded to the perfusion
imaging results. A significant coronary stenosis was defined as > 70%
Index and comparator tests Tachycardic-stress perfusion imaging
• All patients underwent induction of tachycardiac stress via treadmill exercise or
temporary cardiac pacing. Treadmill exercise was performed using the Bruce protocol,
on a symptom-limited basis. Exercise was deemed adequate if peak heart rate was >
75% of the theoretic maximal values, or if exercise was terminated because of angina
pectoris. Pacing was performed in patients unable to attain adequate stress on treadmill
testing. Pacing was performed at the time of cardiac catheterisation, but before
coronary angiography. Myocardial imaging was achieved by IV injection of
technetium-99m tetrofosmin (400 MBq) 1 minute before termination of tachycardiac
stress. Images were acquired on a triple-headed gamma camera with 180° single-
photon emission CT. The images were assessed by nuclear cardiologists who were
blinded to the cardiac catheterisation results.
Follow-up Mean follow-up of 28 ± 10 months.
Notes Informed consent was obtained before study entry.
Table of Methodological Quality Table of Methodological
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes ESKD patients undergoing cardiac evalua-
tion as part of transplant workup
Acceptable reference standard?
All tests
Yes Coronary angiography with a reference
standard threshold of ≥ 70% stenosis
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Worthley 2003 (Continued)
Acceptable delay between tests?
All tests
Yes Tests were done at the same time (author
correspondence).
Partial verification avoided?
All tests
Yes All participants who underwent the index
test received the reference standard test
Differential verification avoided?
All tests
Yes Disease status (CAD) diagnosed by coro-
nary angiography.
Incorporation avoided?
All tests
Yes Disease status (CAD) diagnosed by coro-
nary angiography.
Reference standard results blinded?
All tests
Yes Angiograms were assessed by 2 cardiologists
who were blinded to the perfusion imaging
results
Index test results blinded?
All tests
Yes Images were assessed by nuclear cardiol-
ogists who were blinded to the cardiac
catheterisation results
Relevant clinical information?
All tests
Yes Relevant clinical information was provided
regarding the performance and analysis of
the index and reference tests
Uninterpretable results reported?
All tests
Yes There were no uninterpretable test results.
Withdrawals explained?
All tests
Yes No withdrawals reported.
bpm: beats per minute; CAD: coronary artery disease; CF: cardiac failure; CHF: congestive heart failure; CIMT: carotid intimal medial
thickness; CKD: chronic kidney disease; CVD: cardiovascular disease; DBP: diastolic blood pressure; DM: diabetes mellitus; DSE:
dobutamine stress echocardiogram; DSTS: dipyridamole stress thallium scan; EBCT: electron beam computed tomography; ECG:
electrocardiogram; ESKD: end-stage kidney disease; HTN: hypertension; IHD: ischaemic heart disease; IMT: intimal media thick-
ness; IV: intravenous; MI: myocardial infarction; MIBI: methoxyisobutyl isonitrile stress; MPS: myocardial perfusion scintigraphy;
QCA: quantitative coronary analysis; RRT: renal replacement therapy; RWM: regional wall motion; SBP: systolic blood pressure;
ST: sinus tachycardia; WMA: wall motion abnormality
Characteristics of excluded studies [ordered by study ID]
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Study Reason for exclusion
Ali 2004 Coronary angiography not routinely performed on patients in study
Arantes 2010 Prognostic study; not enough data available to allow for diagnostic accuracy comparison with coronary an-
giography
Braun 1984 No index tests for comparison.
Brown 1989 Prognostic study; not enough data available to allow for diagnostic accuracy comparison with coronary an-
giography
Caglar 2006 Patient population not consisting of patients who are potential transplant recipients; coronary angiography
only provided to patients who tested positive to other tests
Camp 1990 Coronary angiography not used as reference standard.
Cortigiani 2005 Coronary angiography not used as reference standard.
Cottier 1990 Coronary angiography not routinely performed on patients in study
Cross 1996 Prognostic study; not enough data available to allow for diagnostic accuracy comparison with coronary an-
giography
Dahan 1995 Patient population not entirely consisting of patients who are potential transplant recipients. Separate data for
potential transplant recipients not available
Dahan 1998 Patient population not entirely consisting of patients who are potential transplant recipients. Separate data for
potential transplant recipients not available
Dahan 2002 Patient population not entirely consisting of patients who are potential transplant recipients. Separate data for
potential transplant recipients not available
De Vriese 2009 Patient population not entirely consisting of patients who are potential transplant recipients. Roughly 1/3
of the patients that were included in the study were being evaluated for kidney transplantation. The others
consented to have the evaluation as a screening test, because the authors explained to them that the majority
of patients with CAD on dialysis are asymptomatic (author communication). Separate data for potential
transplant recipients not available
Derfler 1991 Coronary angiography not used as reference standard.
Dussol 2004 Coronary angiography not routinely performed on patients in study, only performed on patients who were
index test positive
Eschertzhuber 2005 Coronary angiography not routinely performed on patients in study
Feola 2002 Coronary angiography not used as reference standard.
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(Continued)
Fossati 2004 Data insufficient to construct appropriate 2 x 2 table.
Fujimoto 2006 This was a study of diagnostic accuracy but the patient population did not consist entirely of patients who are
potential transplant recipients. Separate data on patients who were potential transplant recipients not available
Fukui 2005 This was a study of diagnostic accuracy but the patient population did not consist entirely of patients who are
potential transplant recipients. Separate data on patients who were potential transplant recipients not available
Fuster 2000 Coronary angiography not routinely performed on patients in study, only performed on patients who were
index test positive
Holley 1991 Coronary angiography not routinely performed on patients in study; data insufficient to construct appropriate
2 x 2 table
Iqbal 1991 Coronary angiography not used as reference standard.
Jeloka 2007 Coronary angiography not used as reference standard.
Krotin 2007 Coronary angiography not used as reference standard.
Langford 1997 Coronary angiography not used as reference standard.
Le 1994 Prognostic study; not enough data available to allow for diagnostic accuracy comparison with coronary an-
giography
Leonardi 2009 Single centre case experience; not a study of diagnostic accuracy
Lewis 2002 Prognostic study; not enough data available to allow for diagnostic accuracy comparison with coronary an-
giography
Lin 2001 Coronary angiography not used as reference standard.
Ma 2006 Coronary angiography only used in those with high risk scores
Manske 1997 Data insufficient to construct appropriate 2 x 2 table.
Mao 2010 Coronary angiography not used as reference standard.
Mistry 1998 Coronary angiography not used as reference standard.
Morrow 1983 Coronary angiography not used as reference standard.
Nguyen 2007 Coronary angiography not used as reference standard.
Nishimura 2004 This was a study of diagnostic accuracy but the patient population did not consist entirely of patients who are
potential transplant recipients. Separate data on patients who were potential transplant recipients not available
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(Continued)
Ohtake 2005 This was a study of diagnostic accuracy but the patient population did not consist entirely of patients who are
potential transplant recipients. Separate data on patients who were potential transplant recipients not available
Oliveira 2005 Only coronary angiography studied. No other index tests present
Patel 2003 Coronary angiography not used as reference standard.
Patel 2008 Coronary angiography not routinely performed on patients in study
Philipson 1986 Reference standard differentially applied to different treatment groups; unable to construct meaningful 2 x 2
table
Porter 2003 Coronary angiography not used as reference standard.
Rakhit 2006 Coronary angiography not used as reference standard.
Robinson 2007 This was a study of diagnostic accuracy but the patient population did not consist entirely of patients who are
potential transplant recipients. Separate data on patients who were potential transplant recipients not available
Russell 1993 Prognostic study; not enough data available to enable diagnostic accuracy comparison with coronary angiog-
raphy
Schmidt 2001 Patient population not exclusively consisting of patients who are potential transplant recipients; patients were
either those who were on long-term RRT, or who had undergone successful renal transplantation. Separate
data on patients who were potential transplant recipients not available
Sharma 2007 Coronary angiography not used as reference standard.
Tita 2008 Coronary angiography not used as reference standard.
Trochu 1991 Coronary angiography not used as reference standard.
Venkataraman 2008 Coronary angiography not used as reference standard.
Weinrauch 1978 Only coronary angiography studied. No index tests for comparison
Weinrauch 1992 Coronary angiography not used as reference standard.
Witczak 2006 Only coronary angiography studied. No index tests for comparison
Wong 2008 Coronary angiography not used as reference standard.
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D A T A
Presented below are all the data for all of the tests entered into the review.
Tests. Data tables by test
Test
No. of
studies
No. of
participants
1 DSE 13 745
2 MPS 9 582
3 EST 2 129
4 EBCT 1 97
5 DSF 1 86
6 EV 1 35
7 CIMT 1 105
8 Echo (RWMA) 2 265
9 Echo (LV) 1 52
10 Echo (MAC) 1 125
11 ECG 3 263
Test 1. DSE.
Review: Cardiac testing for coronary artery disease in potential kidney transplant recipients
Test: 1 DSE
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bates 1996 9 1 1 6 0.90 [ 0.55, 1.00 ] 0.86 [ 0.42, 1.00 ]
Brennan 1997 4 1 2 5 0.67 [ 0.22, 0.96 ] 0.83 [ 0.36, 1.00 ]
Cai 2010 15 2 8 13 0.65 [ 0.43, 0.84 ] 0.87 [ 0.60, 0.98 ]
De Lima 2003 15 7 19 48 0.44 [ 0.27, 0.62 ] 0.87 [ 0.76, 0.95 ]
Ferreira 2007 24 14 10 78 0.71 [ 0.53, 0.85 ] 0.85 [ 0.76, 0.91 ]
Gang 2007 9 1 10 20 0.47 [ 0.24, 0.71 ] 0.95 [ 0.76, 1.00 ]
Garcia-Canton 1998 11 2 1 13 0.92 [ 0.62, 1.00 ] 0.87 [ 0.60, 0.98 ]
Herzog 1999 12 8 4 26 0.75 [ 0.48, 0.93 ] 0.76 [ 0.59, 0.89 ]
Jassal 2007 0 0 0 18 0.0 [ 0.0, 0.0 ] 1.00 [ 0.81, 1.00 ]
Reis 1995 22 1 1 6 0.96 [ 0.78, 1.00 ] 0.86 [ 0.42, 1.00 ]
Sharma 2005 32 5 4 84 0.89 [ 0.74, 0.97 ] 0.94 [ 0.87, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
(Continued . . . )
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(. . . Continued)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Sharma 2009 36 5 4 95 0.90 [ 0.76, 0.97 ] 0.95 [ 0.89, 0.98 ]
West 2000 12 8 1 12 0.92 [ 0.64, 1.00 ] 0.60 [ 0.36, 0.81 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 2. MPS.
Review: Cardiac testing for coronary artery disease in potential kidney transplant recipients
Test: 2 MPS
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Boudreau 1990 36 8 6 30 0.86 [ 0.71, 0.95 ] 0.79 [ 0.63, 0.90 ]
De Lima 2003 8 10 15 32 0.35 [ 0.16, 0.57 ] 0.76 [ 0.61, 0.88 ]
Garcia-Canton 1998 11 3 1 12 0.92 [ 0.62, 1.00 ] 0.80 [ 0.52, 0.96 ]
Garg 2000 9 4 2 4 0.82 [ 0.48, 0.98 ] 0.50 [ 0.16, 0.84 ]
Gowdak 2010 85 31 52 51 0.62 [ 0.53, 0.70 ] 0.62 [ 0.51, 0.73 ]
Krawczynska 1988 20 18 0 8 1.00 [ 0.83, 1.00 ] 0.31 [ 0.14, 0.52 ]
Marwick 1990 4 9 10 22 0.29 [ 0.08, 0.58 ] 0.71 [ 0.52, 0.86 ]
Vandenberg 1996 10 6 6 19 0.63 [ 0.35, 0.85 ] 0.76 [ 0.55, 0.91 ]
Worthley 2003 13 3 2 22 0.87 [ 0.60, 0.98 ] 0.88 [ 0.69, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 3. EST.
Review: Cardiac testing for coronary artery disease in potential kidney transplant recipients
Test: 3 EST
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bennett 1978 3 1 0 0 1.00 [ 0.29, 1.00 ] 0.0 [ 0.0, 0.97 ]
Sharma 2005 13 8 23 81 0.36 [ 0.21, 0.54 ] 0.91 [ 0.83, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 4. EBCT.
Review: Cardiac testing for coronary artery disease in potential kidney transplant recipients
Test: 4 EBCT
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Rosario 2010 16 25 9 47 0.64 [ 0.43, 0.82 ] 0.65 [ 0.53, 0.76 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 5. DSF.
Review: Cardiac testing for coronary artery disease in potential kidney transplant recipients
Test: 5 DSF
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Marwick 1989 28 17 8 33 0.78 [ 0.61, 0.90 ] 0.66 [ 0.51, 0.79 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 6. EV.
Review: Cardiac testing for coronary artery disease in potential kidney transplant recipients
Test: 6 EV
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Vandenberg 1996 7 7 7 14 0.50 [ 0.23, 0.77 ] 0.67 [ 0.43, 0.85 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 7. CIMT.
Review: Cardiac testing for coronary artery disease in potential kidney transplant recipients
Test: 7 CIMT
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Modi 2006 38 14 4 49 0.90 [ 0.77, 0.97 ] 0.78 [ 0.66, 0.87 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 8. Echo (RWMA).
Review: Cardiac testing for coronary artery disease in potential kidney transplant recipients
Test: 8 Echo (RWMA)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Sharma 2005 11 4 25 85 0.31 [ 0.16, 0.48 ] 0.96 [ 0.89, 0.99 ]
Sharma 2009 13 5 27 95 0.33 [ 0.19, 0.49 ] 0.95 [ 0.89, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 9. Echo (LV).
Review: Cardiac testing for coronary artery disease in potential kidney transplant recipients
Test: 9 Echo (LV)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Garg 2000 8 5 19 20 0.30 [ 0.14, 0.50 ] 0.80 [ 0.59, 0.93 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 10. Echo (MAC).
Review: Cardiac testing for coronary artery disease in potential kidney transplant recipients
Test: 10 Echo (MAC)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Sharma 2005 22 25 14 64 0.61 [ 0.43, 0.77 ] 0.72 [ 0.61, 0.81 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 11. ECG.
Review: Cardiac testing for coronary artery disease in potential kidney transplant recipients
Test: 11 ECG
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Gang 2007 9 12 10 9 0.47 [ 0.24, 0.71 ] 0.43 [ 0.22, 0.66 ]
Garg 2000 51 1 22 24 0.70 [ 0.58, 0.80 ] 0.96 [ 0.80, 1.00 ]
Sharma 2005 27 14 9 75 0.75 [ 0.58, 0.88 ] 0.84 [ 0.75, 0.91 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
A D D I T I O N A L T A B L E S
Table 1. Description of index tests
Test Description Advantages Disadvantages Type of result Presence of cut-off
values
Screening tests Screening tests
MPS
Stress
Exercise
dipyridamole
dobutamine
Radionucleotide
thallium-201 or Tc-
99m sestamibi ra-
dionucleotide agents
This compares per-
fusion of my-
ocardium at rest and
after a ‘stress’ such as
exercise or drugs (e.
g. dipyridamole).
When coronary ar-
teries are normal,
‘stress’ results in va-
sodilatation and in-
creased coronary
blood flow. How-
ever, diseased coro-
nary arteries cannot
Non-invasive
Provides
information regard-
ing functional status
of myocardium un-
der stress conditions
Neither 100% sen-
sitive nor specific
Radiation dose
Results subject to
interpretation and
reader bias
False positives due
to increase in at-
tenuation artefacts
caused by left ven-
tricular hypertrophy
False negatives
due to balanced is-
chaemia (e.g. triple
vessel disease)
Dichotomous (i.e.
stress test positive or
stress test negative)
None. However,
whether a stress test
is interpreted as pos-
itive or negative de-
pends largely on ob-
server interpretation
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Table 1. Description of index tests (Continued)
dilate because they
are already maxi-
mally dilated and
there is no increase
in blood flow af-
ter a stress. MPS
reveals these areas
as regions of de-
creased perfusion. A
reversible perfusion
defect is a sign of is-
chaemia. A fixed de-
fect (when there is
decreased perfusion
before, during and
after the stress) is an
indicator of infarc-
tion
Pharmacologi-
cal agents overcome
limitations of exer-
cise testing in pa-
tients with kidney
disease
More expensive
than exercise ECG
DSE
Stress
Exercise
dobutamine
Stress echocardiog-
raphy compares the
regional wall
motion and thick-
ness of myocardium
both at rest and af-
ter stress. Regional
systolic dysfunction
is usually caused by
CAD
Pharmacologi-
cal stress agent over-
comes limitations of
exercise testing in
patients with kidney
disease
Non-invasive
No radiation dose
Provides
information regard-
ing functional status
of myocardium un-
der stress conditions
Provides assessment
of ventricular size
and function
Neither 100% sen-
sitive nor specific
Results subject to
interpretation and
reader bias
Operator
dependent
Acoustic windows
not possible in up to
20% of subjects
Hyper-
tensive response to
stress agent possible
Cardiomyopathies
may also show re-
gional variation in
function
Dichotomous (i.e.
stress test positive or
stress test negative)
None. However,
whether a stress test
is interpreted as pos-
itive or negative de-
pends largely on ob-
server interpretation
Exercise ECG
Bruce protocol stress
ECG
Patient exercises on
a
treadmill while con-
nected to an ECG.
The level of exercise
is increased in pro-
gressive stages. The
Non-invasive
Provides
information regard-
ing functional status
of myocardium un-
der stress conditions
Neither 100% sen-
sitive nor specific
Results subject to
interpretation and
reader bias
Often limited by the
Dichotomous (i.e.
stress test positive or
stress test negative)
No. However,
whether a stress test
is interpreted as pos-
itive or negative de-
pends largely on ob-
server interpretation
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Table 1. Description of index tests (Continued)
patient’s symptoms
and blood pressure
response are
checked repeatedly.
Ischaemic ECG
changes or angina
symptoms brought
on by exercise are
highly suggestive of
underlying CAD
inabil-
ity of CKD patients
to achieve an ade-
quate peak exercise
workload, develop-
ment of exercise-in-
duced hypotension
High pro-
portion have abnor-
mal baseline ECG
(left ventricular hy-
pertrophy)
Coronary artery
calcium score
EBCT
Multidetector com-
puted tomography
Car-
diac calcium scoring
is a non-invasive test
that uses computed
tomography to de-
tect the presence of
calcium in plaque
on the walls of the
arteries of the heart
(coronary arteries).
A calcium score is
then derived, calcu-
lated as a summa-
tion of all calcified
lesions in the coro-
nary arteries. The
calcium score is then
compared with a
reference range ap-
propriate to a pa-
tient’s age and sex.
High calcium scores
are associated with
higher risks of car-
diovascular events
Non-invasive Neither 100% sen-
sitive nor specific
Radiation dose
Continuous There is no uni-
formly agreed cut-
off value at which
patients are consid-
ered at high risk of
CAD. We planned
to analyse results
by combining data
from studies which
share identical cut-
off values
Echocardiography
Trans-thoracic
Trans-oesophageal
An ultrasound of
the heart that en-
ables assessment of
structure and func-
tion
Impairment in sys-
tolic function can
result from pre-ex-
isting CAD
Provides in-
formation regarding
myocardial function
and
regional wall abnor-
malities, which may
suggest pre-existing
ischaemia or MI
Enables assessment
of structure
Neither highly sen-
sitive nor specific
Does not provide
any information of
reversible ischaemia
Results subject to
interpretation and
reader bias
Dichotomous (e.g.
presence or absence
of resting wall mo-
tion abnormality)
None
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Table 1. Description of index tests (Continued)
CT coronary an-
giography
Specialised
form of CT that en-
ables imaging of the
heart and comput-
erised recon-
struction of coro-
nary arteries, per-
mitting assessment
of the lumen and
vessel walls
Non-invasive
Enables diagnosis of
precise location and
severity of each le-
sion as opposed to
vascular territory af-
fected, as is the case
for most functional
tests
Assesses not only the
lumen of the ves-
sel but also the wall.
It can also demon-
strate soft atheroma-
tous plaques, which
cannot be demon-
strated on conven-
tional coronary an-
giography
Radiation dose
Contrast nephropa-
thy
Inability to provide
opportunity
for immediate inter-
vention (as opposed
to coronary angiog-
raphy)
Dichotomous (i.e.
presence or absence
of significant CAD)
Yes (i.e. ≥ 50%
stenosis or ≥ 70%
stenosis)
We planned to man-
age the issue of dif-
ferent cut points by
involving an analy-
sis that included:
• All studies
regardless of
threshold of CAD
on coronary
angiography (these
will include both
studies which have
≥ 50% stenosis and
≥ 70% stenosis
• Only studies
which had ≥ 70%
stenosis threshold
Cardiac magnetic
resonance imaging
MRI of the heart
that enables evalua-
tion of its structure
and function
Non-invasive
No radiation dose
Enables assessment
of structure of my-
ocardium
High spatial reso-
lution means low
inter-observer vari-
ability
Neither highly sen-
sitive nor specific
Dichotomous
(e.g. presence or ab-
sence of left ven-
tricular systolic dys-
function)
None
Resting ECG Transthoracic inter-
pretation of the elec-
trical activity of the
heart over time cap-
tured and externally
recorded by skin
electrodes
Provides in-
formation regarding
the elec-
trical function of the
myocardium, which
may suggest pre-ex-
isting ischaemia, left
ventric-
ular hypertrophy or
arrhythmias
Neither sensitive
nor specific
Does not provide
any information of
reversible ischaemia
Dichotomous (i.e.
presence or absence
of certain ECG fea-
tures)
None
CIMT Measurement of the
thickness of artery
walls, usually by ex-
ternal ultrasound, to
detect both the pres-
ence and to track
the progression of
Non-invasive Neither highly sen-
sitive nor specific
Does not provide
any information on
cardiac function
Continuous Yes. This will vary
depending on the
institution (e.g. 0.
75 mm)
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Table 1. Description of index tests (Continued)
atherosclerotic dis-
ease in
humans. Used as a
surrogate marker for
atherosclerosis
Cardiopulmonary
exercise testing
Evaluates both car-
diac and pulmonary
func-
tion. Cardiac func-
tion is evaluated in
terms of aerobic ca-
pacity and respira-
tory function
The subject is ex-
ercised on a bi-
cycle ergometer or
treadmill. The test
enables calculation
of maximal aero-
bic capacity and the
point during exer-
cise where anaerobic
metabolism is used
to supplement aer-
obic metabolism as
a source of energy.
These can be mea-
sured via gas ex-
change data
Non-invasive mea-
surement of ventric-
ular function, respi-
ratory function and
cellular function via
measurement of gas
exchange, as well
as detection of my-
ocardial ischaemia
Excellent method
of evaluating fitness
and operative fitness
Not commonly per-
formed
Dichotomous (e.g.
stress ECG positive
or stress ECG nega-
tive; presence or ab-
sence of cardiac fail-
ure) and
Contin-
uous (e.g. measure-
ment of the max-
imum aerobic ca-
pacity and anaero-
bic threshold)
Yes, although these
will vary for dif-
ferent variables and
for different institu-
tions
DSF Used to detect coro-
nary artery calcifi-
cation. Digital sub-
traction
improves resolution
of conventional flu-
oroscopic methods
Non-invasive
Non exercise
Not commonly
used
Radiation dose
Dichotomous (i.e.
presence or absence
of calcification)
None
Exercise radionu-
cleotide ventricu-
lography
Technique
for a combined as-
sessment of exercise
capacity and an eval-
uation of ventricu-
lar size and perfor-
mance
Not commonly
used
Radiation dose
Dichotomous (i.e.
stress test positive or
stress test negative)
None. However,
whether a stress test
is interpreted as pos-
itive or negative de-
pends largely on ob-
server interpretation
Reference standard Reference standar
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